Multi-sensor patient monitor to detect impending cardiac decompensation

Information

  • Patent Grant
  • 8790257
  • Patent Number
    8,790,257
  • Date Filed
    Friday, September 12, 2008
    15 years ago
  • Date Issued
    Tuesday, July 29, 2014
    9 years ago
Abstract
Systems and methods of detecting an impending cardiac decompensation of a patient measure at least two of an electrocardiogram signal of the patient, a hydration signal of the patient, a respiration signal of the patient or an activity signal of the patient. The at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are combined with an algorithm to detect the impending cardiac decompensation.
Description

The subject matter of the present application is related to the following applications: 60/972,329; 60/972,354; 60/972,616; 60/972,363; 60/972,343; 60/972,581; 60/972,629; 60/972,316; 60/972,333; 60/972,359; 60/972,336; 60/972,340 all of which were filed on Sep. 14, 2007; 61/046,196 filed Apr. 18, 2008; 61/047,875 filed Apr. 25, 2008; 61/055,645, 61/055,656, 61/055,662 all filed May 23, 2008; and 61/079,746 filed Jul. 10, 2008.


The following applications are being filed concurrently with the present application, on Sep. 12, 2008: application Ser. No. 12/209,288 entitled “Adherent Device with Multiple Physiological Sensors”; application Ser. No. 12/209,430 entitled “Injectable Device for Physiological Monitoring”; application Ser. No. 12/209,479 entitled “Delivery System for Injectable Physiological Monitoring System”; application Ser. No. 12/209,262 entitled “Adherent Device for Cardiac Rhythm Management”; application Ser. No. 12/209,268 entitled “Adherent Device for Respiratory Monitoring”; application Ser. No. 12/209,269 entitled “Adherent Athletic Monitor”; application Ser. No. 12/209,259 entitled “Adherent Emergency Monitor”; application Ser. No. 12/209,273 entitled “Adherent Device with Physiological Sensors”; application Ser. No. 12/209,276 entitled “Medical Device Automatic Start-up upon Contact to Patient Tissue”; application Ser. No. 12/210,078 entitled “System and Methods for Wireless Body Fluid Monitoring”; application Ser. No. 12/209,265 entitled “Adherent Cardiac Monitor with Advanced Sensing Capabilities”; application Ser. No. 12/209,292 entitled “Adherent Device for Sleep Disordered Breathing”; application Ser. No. 12/209,278 entitled “Dynamic Pairing of Patients to Data Collection Gateways”; application Ser. No. 12/209,508 entitled “Adherent Multi-Sensor Device with Implantable Device Communications Capabilities”; application Ser. No. 12/209,528 entitled “Data Collection in a Multi-Sensor Patient Monitor”; application Ser. No. 12/209,271 entitled “Adherent Multi-Sensor Device with Empathic Monitoring”; application Ser. No. 12/209,274 entitled “Energy Management for Adherent Patient Monitor”; and application Ser. No. 12/209,294 “Tracking and Security for Adherent Patient Monitor.”


BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to patient monitoring, and more specifically to patient monitoring to detect and/or avoid impending cardiac decompensation. Although embodiments make specific reference to monitoring impedance and electrocardiogram signals with an adherent patch, the system methods and device described herein may be applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implantable devices for extended periods.


Patients are often treated for diseases and/or conditions associated with a compromised status of the patient, for example a compromised physiologic status such as heart disease. In some instances a patient may have suffered a heart attack and require care and/or monitoring after release from the hospital. While such long term care may be at least partially effective, many patients are not sufficiently monitored and eventually succumb to cardiac decompensation, or heart failure. One example of a device that may be used to monitor a patient is the Holter monitor, or ambulatory electrocardiography device. Although such a device may be effective in measuring electrocardiography, such measurements alone may not be sufficient to reliably detect and/or avoid an impending cardiac decompensation.


In addition to measuring heart signals with electrocardiograms, known physiologic measurements include impedance measurements. For example, transthoracic impedance measurements can be used to measure hydration and respiration. Although transthoracic measurements can be useful, such measurements may use electrodes that are positioned across the midline of the patient, and may be somewhat uncomfortable and/or cumbersome for the patient to wear.


Work in relation to embodiments of the present invention suggests that known methods and apparatus for long term monitoring of patients may be less than ideal to detect and/or avoid an impending cardiac decompensation. In at least some instances, cardiac decompensation can be difficult to detect, for example in the early stages. At least some of the known devices may not collect the right kinds of data to treat patients optimally. For example, although successful at detecting and storing electrocardiogram signals, devices such as the Holter monitor can be somewhat bulky and may not collect all of the kinds of data that would be ideal to diagnose and/or treat a patient, for example to detect decompensation. In at least some instances, devices that are worn by the patient may be somewhat uncomfortable, which may lead to patients not wearing the devices and not complying with direction from the health care provider, such that data collected may be less than ideal. Although implantable devices may be used in some instances, many of these devices can be invasive and/or costly, and may suffer at least some of the shortcomings of known wearable devices. As a result, at least some patient are not adequately monitored, and may go into cardiac decompensation, or even die. Work in relation to embodiments of the present invention suggests that improved monitoring may avoid patient trauma, save lives, and decrease health care costs.


Therefore, a need exists for improved patient monitoring. Ideally, such improved patient monitoring would avoid at least some of the short-comings of the present methods and devices.


2. Description of the Background Art


The following U.S. Patents and Publications may describe relevant background art: U.S. Pat. Nos. 4,121,573; 4,955,381; 4,981,139; 5,080,099; 5,353,793; 5,469,859; 5,511,553; 5,544,661; 5,558,638; 5,724,025; 5,772,586; 5,862,802; 6,047,203; 6,117,077; 6,129,744; 6,225,901; 6,308,094; 6,385,473; 6,416,471; 6,454,707; 6,454,708; 6,527,711; 6,527,729; 6,551,252; 6,595,927; 6,595,929; 6,605,038; 6,645,153; 6,821,249; 6,980,851; 7,020,508; 7,054,679; 7,153,262; 7,160,252; 2004/133079; 2004/152956; 2005/0113703; 2005/0131288; 2006/0010090; 2006/0031102; 2006/0089679; 2006/122474; 2006/0155183; 2006/0224051; 2006/0264730; 2007/0021678; 2007/0038038; 2005/256418; 2005/137626; and 2006/161459. The following PCT Publication(s) may also describe relevant background art: WO2006/111878.


BRIEF SUMMARY OF THE INVENTION

Embodiments of the present invention provide systems and methods for the detection of an impending cardiac decompensation. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and/or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring impedance and electrocardiogram signals with an adherent patch, the system methods and device described herein may be applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods.


In a first aspect, embodiments of the present invention provide a method of detecting an impending cardiac decompensation of a patient. At least two of an electrocardiogram signal of the patient, a hydration signal of the patient, a respiration signal of the patient or an activity signal of the patient are measured. The at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are combined to detect the impending cardiac decompensation. In many embodiments, the impending decompensation can be detected at least 24 hours before the decompensation occurs, for example 72 hours, and in many embodiments with a confidence level of at least 80%, for example 90%.


In many embodiments, the at least two comprise at least three of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal, and the at least three are measured and combined to detect the impending cardiac decompensation. In specific embodiments, the at least three comprise at least four of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal, and the at least four are measured and combined to detect the impending cardiac decompensation.


In specific embodiments, the electrocardiogram signal, the hydration signal, the respiration signal and the activity signal are measured combined to detect the impending cardiac decompensation.


In many embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal can be used simultaneously to determine impending cardiac decompensation. The at least two signals can be used simultaneously in many ways.


In many embodiments, combining comprises using the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to look up a value in a previously existing array. In some embodiments, combining may comprise at least one of adding, subtracting, multiplying, scaling or dividing the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. In some embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal can be combined with at least one of a weighted combination, a tiered combination or a logic gated combination, a time weighted combination or a rate of change.


In many embodiments, a flag status is determined in response to the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. The flag status can be determined in response to a change in the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. In some embodiments, additional signal measurements of the patient can be made in response to the flag status.


In many embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are combined in response to a time of day.


In many embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal may comprise at least one of a derived signal, a time averaged signal, a filtered signal or a raw signal.


In many embodiments, baseline values of the patient for the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are determined, and the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal signals comprise changes from the baseline values.


In many embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal comprise differences from population baseline values, and the impending decompensation is detected in response to the differences from the baseline values of the patient population.


In many embodiments, the hydration signal comprises an impedance signal and the activity signal comprise an accelerometer signal.


In many embodiments, the activity signal may comprise an accelerometer signal to indicate a posture of the patient. In specific embodiments, the accelerometer signal may comprise a three dimensional inclination signal to determine a three dimensional orientation of the patient.


In many embodiments, a temperature signal is combined with the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to detect the impending cardiac decompensation.


In many embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are transmitted to a remote site where the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are combined to detect the impending cardiac decompensation.


In many embodiments, instructions are transmitted from a remote site to a processor supported with the patient, and the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are combined with the processor in response to the instructions to detect the impending cardiac decompensation.


In another aspect, embodiments of the present invention provide a system to detect impending cardiac decompensation of a patient. The system comprises circuitry to measure at least two of an electrocardiogram signal of the patient, a hydration signal of the patient, or an activity signal of the patient. A processor system comprising a tangible medium in communication with the circuitry is configured to combine the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to detect the impending cardiac decompensation.


In some embodiments, the processor system comprises a least one processor remote from the patient configured to combine the at least two to detect the decompensation.


In some embodiments, the processor system comprises a processor supported with the patient configured to receive instructions transmitted from a remote site and combine the at least two in response to the instructions to detect the impending cardiac decompensation.


In many embodiments, the at least two comprise at least three of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal and the at least three are measured and combined to detect the impending cardiac decompensation. In specific embodiments, the at least three comprise at least four of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal and the at least four are measured and combined to detect the impending cardiac decompensation.


In specific embodiments, the processor system simultaneously uses the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to determine impending cardiac decompensation. The at least two signals can be used simultaneously in many ways,


In many embodiments, combining comprises the processor system using the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to look up a value in a previously existing array. In some embodiments, combining comprises at least one of adding, subtracting, multiplying, scaling or dividing the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. In some embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal, or the activity signal can be combined with at least one of a weighted combination, a tiered combination or a logic gated combination, a time weighted combination or a rate of change.


In many embodiments, the processor system determines a flag status in response to the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. The processor system determines the flag status in response to a change in the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. In some embodiments, the processor system affects the circuitry to make additional signal measurements of the patient in response to the flag status.


In many embodiments, the processor system combines the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal in response to a time of day.


In many embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal comprise at least one of a derived signal, a time averaged signal, a filtered signal or a raw signal.


In many embodiments, the processor determines baseline values of the patient for the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. The at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal signals may comprise changes from the baseline values.


In many embodiments, the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal comprise differences from baseline values of a patient population. The impending decompensation is detected in response to the differences from the baseline value of the patient population.


In many embodiments, the hydration signal comprises an impedance signal and the activity signal comprise an accelerometer signal.


In many embodiments, the activity signal may comprise an accelerometer signal to determine a posture of the patient. In specific embodiments, the accelerometer signal may comprise a three dimensional inclination signal to determine a three dimensional orientation of the patient.


In many embodiments, the processor system combines a temperature signal with the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to detect the impending cardiac decompensation.


In many embodiments, the processor transmits the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to a remote site where the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal are combined to detect the impending cardiac decompensation.


In many embodiments, instructions are transmitted from a remote site to a processor supported with the patient. The processor combines at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal in response to the instructions to detect the impending cardiac decompensation





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A shows a patient and a monitoring system comprising an adherent device, according to embodiments of the present invention;



FIG. 1B shows a bottom view of the adherent device as in FIG. 1A comprising an adherent patch;



FIG. 1C shows a top view of the adherent patch, as in FIG. 1B;



FIG. 1D shows a printed circuit boards and electronic components over the adherent patch, as in FIG. 1C;



FIG. 1D-1 shows an equivalent circuit that can be used to determine optimal frequencies for determining patient hydration, according to embodiments of the present invention;



FIG. 1E shows batteries positioned over the printed circuit board and electronic components as in FIG. 1D;



FIG. 1F shows a top view of an electronics housing and a breathable cover over the batteries, electronic components and printed circuit board as in FIG. 1E;



FIG. 1G shows a side view of the adherent device as in FIGS. 1A to 1F;



FIG. 1H shown a bottom isometric view of the adherent device as in FIGS. 1A to 1G;



FIG. 2A shows a method of predicting an impending cardiac decompensation, according to embodiments of the present invention; and



FIGS. 3A and 3B show clinical data measured with an adherent patch device.





DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the present invention provide systems and methods for the detection of an impending cardiac decompensation. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and/or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring impedance and electrocardiogram signals with an adherent patch, the system methods and device described herein may be applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods. In some embodiments, implanted sensors may be used, for example as described in U.S. Pat. Nos. 6,208,894; 6,315,721; 6,185,452; and U.S. Application No. 60/972,329, entitled “Injectable Device for Physiological Monitoring” filed on Sep. 14, 2007, the same day as the present application with the same assignee, the full disclosures of which are incorporated by reference.


Decompensation is failure of the heart to maintain adequate blood circulation. Although the heart can maintain at least some pumping of blood, the quantity is inadequate to maintain healthy tissues. Several symptoms can result from decompensation including pulmonary congestion, breathlessness, faintness, cardiac palpitation, edema of the extremities, and enlargement of the liver. Cardiac decompensation can result in slow or sudden death. Sudden Cardiac Arrest (hereinafter “SCA”), also referred to as sudden cardiac death, is an abrupt loss of cardiac pumping function that can be caused by a ventricular arrhythmia, for example ventricular tachycardia and/or ventricular fibrillation. Although decompensation and SCA can be related in that patients with decompensation are also at an increased risk for SCA, decompensation is primarily a mechanical dysfunction caused by inadequate blood flow, and SCA is primarily an electrical dysfunction caused by inadequate and/or inappropriate electrical signals of the heart.



FIG. 1A shows a patient P and a monitoring system 10. Patient P comprises a midline M, a first side S1, for example a right side, and a second side S2, for example a left side. Monitoring system 10 comprises an adherent device 100. Adherent device 100 can be adhered to a patient P at many locations, for example thorax T of patient P. In many embodiments, the adherent device may adhere to one side of the patient, from which data from the one side can be collected. Work in relation with embodiments of the present invention suggests that location on a side of the patient can provide comfort for the patient while the device is adhered to the patient.


Monitoring system 10 includes components to transmit data to a remote center 106. Adherent device 100 can communicate wirelessly to an intermediate device 102, for example with a single wireless hop from the adherent device on the patient to the intermediate device. Intermediate device 102 can communicate with remote center 106 in many ways, for example with an internet connection. In many embodiments, monitoring system 10 comprises a distributed processing system with at least one processor on device 100, at least one processor on intermediate device 102, and at least one process at remote center 106, each of which processors is in electronic communication with the other processors. Remote center 106 can be in communication with a health care provider 108A with a communication system 107A, such as the Internet, an intranet, phone lines, wireless and/or satellite phone. Health care provider 108A, for example a family member, can be in communication with patient P with a communication, for example with a two way communication system, as indicated by arrow 109A, for example by cell phone, email, landline. Remote center 106 can be in communication with a health care professional, for example a physician 108B, with a communication system 107B, such as the Internet, an intranet, phone lines, wireless and/or satellite phone. Physician 108B can be in communication with patient P with a communication, for example with a two way communication system, as indicated by arrow 109B, for example by cell phone, email, landline. Remote center 106 can be in communication with an emergency responder 108C, for example a 911 operator and/or paramedic, with a communication system 107C, such as the Internet, an intranet, phone lines, wireless and/or satellite phone. Emergency responder 108C can travel to the patient as indicated by arrow 109C. Thus, in many embodiments, monitoring system 10 comprises a closed loop system in which patient care can be monitored and implemented from the remote center in response to signals from the adherent device.


In many embodiments, the adherent device may continuously monitor physiological parameters, communicate wirelessly with a remote center, and provide alerts when necessary. The system may comprise an adherent patch, which attaches to the patient's thorax and contains sensing electrodes, battery, memory, logic, and wireless communication capabilities. In some embodiments, the patch can communicate with the remote center, via the intermediate device in the patient's home. In the many embodiments, the remote center receives the data and applies the prediction algorithm. When a flag is raised, the center may communicate with the patient, hospital, nurse, and/or physician to allow for therapeutic intervention to prevent decompensation.


The adherent device may be affixed and/or adhered to the body in many ways. For example, with at least one of the following an adhesive tape, a constant-force spring, suspenders around shoulders, a screw-in microneedle electrode, a pre-shaped electronics module to shape fabric to a thorax, a pinch onto roll of skin, or transcutaneous anchoring. Patch and/or device replacement may occur with a keyed patch (e.g. two-part patch), an outline or anatomical mark, a low-adhesive guide (place guide|remove old patch|place new patch|remove guide), or a keyed attachment for chatter reduction. The patch and/or device may comprise an adhesiveless embodiment (e.g. chest strap), and/or a low-irritation adhesive model for sensitive skin. The adherent patch and/or device can comprise many shapes, for example at least one of a dogbone, an hourglass, an oblong, a circular or an oval shape.


In many embodiments, the adherent device may comprise a reusable electronics module with replaceable patches (the module collects cumulative data for approximately 90 days) and/or the entire adherent component (electronics+patch) may be disposable. In a completely disposable embodiment, a “baton” mechanism may be used for data transfer and retention, for example baton transfer may include baseline information. In some embodiments, the device may have a rechargeable module, and may use dual battery and/or electronics modules, wherein one module 101A can be recharged using a charging station 103 while the other module 101B is placed on the adherent device. In some embodiments, the intermediate device 102 may comprise the charging module, data transfer, storage and/or transmission, such that one of the electronics modules can be placed in the intermediate device for charging and/or data transfer while the other electronics module is worn by the patient.


In many embodiments, the system can perform the following functions: initiation, programming, measuring, storing, analyzing, communicating, predicting, and displaying. The adherent device may contain a subset of the following physiological sensors: bioimpedance, respiration, respiration rate variability, heart rate (average, minimum, maximum), heart rhythm, HRV, HRT, heart sounds (e.g. S3), respiratory sounds, blood pressure, activity, posture, wake/sleep, orthopnea, temperature/heat flux, and weight. The activity sensor may be one of the following: ball switch, accelerometer, minute ventilation, HR, bioimpedance noise, skin temperature/heat flux, BP, muscle noise, posture.


In many embodiments, the patch wirelessly communicates with a remote center. In some embodiments, the communication may occur directly (via a cellular or Wi-Fi network), or indirectly through intermediate device 102. Intermediate device 102 may consist of multiple devices which communicate wired or wirelessly to relay data to remote center 106.



FIG. 1B shows a bottom view of adherent device 100 as in FIG. 1A comprising an adherent patch 110. Adherent patch 110 comprises a first side, or a lower side 110A, that is oriented toward the skin of the patient when placed on the patient. In many embodiments, adherent patch 110 comprises a tape 110T which is a material, preferably breathable, with an adhesive 116A. Patient side 110A comprises adhesive 116A to adhere the patch 110 and adherent device 100 to patient P. Electrodes 112A, 112B, 112C and 112D are affixed to adherent patch 110. In many embodiments, at least four electrodes are attached to the patch, for example six electrodes. In some embodiments the patch comprises at least two electrodes, for example two electrodes to measure an electrocardiogram (ECG) of the patient. Gel 114A, gel 114B, gel 114C and gel 114D can each be positioned over electrodes 112A, 112B, 112C and 112D, respectively, to provide electrical conductivity between the electrodes and the skin of the patient. In many embodiments, the electrodes can be affixed to the patch 110, for example with known methods and structures such as rivets, adhesive, stitches, etc. In many embodiments, patch 110 comprises a breathable material to permit air and/or vapor to flow to and from the surface of the skin.



FIG. 1C shows a top view of the adherent patch 100, as in FIG. 1B. Adherent patch 100 comprises a second side, or upper side 110B. In many embodiments, electrodes 110A, 110B, 110C and 110D extend from lower side 110A through the adherent patch to upper side 110B. In some embodiments, an adhesive 116B can be applied to upper side 110B to adhere structures, for example, a cover, to the patch such that the patch can support the electronics and other structures when the patch is adhered to the patient. The printed circuit board (PCB) comprise completely flex PCB, rigid PCB combined flex PCB and/or rigid PCB boards connected by cable.



FIG. 1D shows a printed circuit boards and electronic components over adherent patch 110, as in FIG. 1C. A printed circuit board (PCB), for example flex PCB 120, can be positioned above 110B of patch 110. Flex PCB 120 can include traces that extends to connectors 122A, 122B, 122C and 122D on the flex PCB. Connectors 122A, 122B, 122C and 122D can be positioned on flex PCB 120 in alignment with electrodes 112A, 112B, 112C and 112D so as to electrically couple the flex PCB with the electrodes. In some embodiments, connectors 122A, 122B, 122C and 122D may comprise insulated wires or a flex circuit that provide strain relief between the PCB and the electrodes. In some embodiments, additional PCB's for example PCB 120A, 120B, 120C and 120D be connected to flex PCB 120. Electronic components 130 can be connected to flex PCB 120 and/or mounted thereon. In some embodiments, electronic components 130 can be mounted on the additional PCB's.


Electronic components 130 comprise components to take physiologic measurements, transmit data to remote center 106 and receive commands from remote center 106. In many embodiments, electronics components 130 may comprise known low power circuitry, for example complementary metal oxide semiconductor (CMOS) circuitry components. Electronics components 130 comprise an activity sensor and activity circuitry 134, impedance circuitry 136 and electrocardiogram circuitry, for example ECG circuitry 136. In some embodiments, electronics circuitry 130 may comprise a microphone and microphone circuitry 142 to detect an audio signal from within the patient, and the audio signal may comprise a heart sound and/or a respiratory sound, for example an S3 heart sound and a respiratory sound with rales and/or crackles. Electronics circuitry 130 may comprise a temperature sensor, for example a thermistor, and temperature sensor circuitry 144 to measure a temperature of the patient, for example a temperature of a skin of the patient. Electronics circuitry may comprise a heat flux sensor and heat flux sensor circuitry to measure a skin heat flow of a patient.


Work in relation to embodiments of the present invention suggests that skin temperature may effect impedance and/or hydration measurements, and that skin temperature measurements may be used to correct impedance and/or hydration measurements. In some embodiments, increase in skin temperature can be associated with increased vaso-dilation near the skin surface, such that measured impedance measurement decreased, even through the hydration of the patient in deeper tissues under the skin remains substantially unchanged. Thus, use of the temperature sensor can allow for correction of the hydration signals to more accurately assess the hydration, for example extra cellular hydration, of deeper tissues of the patient, for example deeper tissues in the thorax.


Electronics circuitry 130 may comprise a processor 146. Processor 146 comprises a tangible medium, for example read only memory (ROM), electrically erasable programmable read only memory (EEPROM) and/or random access memory (RAM). Electronic circuitry 130 may comprise real time clock and frequency generator circuitry 148. In some embodiments, processor 136 may comprise the frequency generator and real time clock. The processor can be configured to control a collection and transmission of data from the impedance circuitry electrocardiogram circuitry and the accelerometer. In many embodiments, device 100 comprise a distributed processor system, for example with multiple processors on device 100.


In many embodiments, electronics components 130 comprise wireless communications circuitry 132 to communicate with remote center 106. The wireless communication circuitry can be coupled to the impedance circuitry, the electrocardiogram circuitry and the accelerometer to transmit to a remote center with a communication protocol at least one of the hydration signal, the electrocardiogram signal or the accelerometer signal. In specific embodiments, wireless communication circuitry is configured to transmit the hydration signal, the electrocardiogram signal and the accelerometer signal to the remote center with a single wireless hop, for example from wireless communication circuitry 132 to intermediate device 102. The communication protocol comprises at least one of Bluetooth, Zigbee, WiFi, WiMax, IR, amplitude modulation or frequency modulation. In many embodiments, the communications protocol comprises a two way protocol such that the remote center is capable of issuing commands to control data collection.


In some embodiments, intermediate device 102 comprises a data collection system to collect and store data from the wireless transmitter. The data collection system can be configured to communicate periodically with the remote center. In many embodiments, the data collection system can transmit data in response to commands from remote center 106 and/or in response to commands from the adherent device.


Activity sensor and activity circuitry 134 can comprise many known activity sensors and circuitry. In many embodiments, the accelerometer comprises at least one of a piezoelectric accelerometer, capacitive accelerometer or electromechanical accelerometer. The accelerometer may comprise a 3-axis accelerometer to measure at least one of an inclination, a position, an orientation or acceleration of the patient in three dimensions. Work in relation to embodiments of the present invention suggests that three dimensional orientation of the patient and associated positions, for example sitting, standing, lying down, can be very useful when combined with data from other sensors, for example ECG data and/or hydration data.


Impedance circuitry 136 can generate both hydration data and respiration data. In many embodiments, impedance circuitry 136 is electrically connected to electrodes 112A, 112B, 112C and 112D such that electrodes 112A and 112D comprise outer electrodes that are driven with a current, or force electrodes. The current delivered between electrodes 112A and 112D generates a measurable voltage between electrodes 112B and 112C, such that electrodes 112B and 112C comprise inner electrodes, or sense electrodes that measure the voltage in response to the current from the force electrodes. The voltage measured by the sense electrodes can be used to determine the hydration of the patient.



FIG. 1D-1 shows an equivalent circuit 152 that can be used to determine optimal frequencies for measuring patient hydration. Work in relation to embodiments of the present invention indicates that the frequency of the current and/or voltage at the force electrodes can be selected so as to provide impedance signals related to the extracellular and/or intracellular hydration of the patient tissue. Equivalent circuit 152 comprises an intracellular resistance 156, or R(ICW) in series with a capacitor 154, and an extracellular resistance 158, or R(ECW). Extracellular resistance 158 is in parallel with intracellular resistance 156 and capacitor 154 related to capacitance of cell membranes. In many embodiments, impedances can be measured and provide useful information over a wide range of frequencies, for example from about 0.5 kHz to about 200 KHz. Work in relation to embodiments of the present invention suggests that extracellular resistance 158 can be significantly related extracellular fluid and to cardiac decompensation, and that extracellular resistance 158 and extracellular fluid can be effectively measured with frequencies in a range from about 0.5 kHz to about 20 kHz, for example from about 1 kHz to about 10 kHz. In some embodiments, a single frequency can be used to determine the extracellular resistance and/or fluid. As sample frequencies increase from about 10 kHz to about 20 kHz, capacitance related to cell membranes decrease the impedance, such that the intracellular fluid contributes to the impedance and/or hydration measurements. Thus, many embodiments of the present invention employ measure hydration with frequencies from about 0.5 kHz to about 20 kHz to determine patient hydration.


In many embodiments, impedance circuitry 136 can be configured to determine respiration of the patient. In specific embodiments, the impedance circuitry can measure the hydration at 25 Hz intervals, for example at 25 Hz intervals using impedance measurements with a frequency from about 0.5 kHz to about 20 kHz.


ECG circuitry 138 can generate electrocardiogram signals and data from electrodes 112A, 112B, 112C and 112D. In some embodiments, ECG circuitry 138 is connected to inner electrodes 12B and 122C, which may comprise sense electrodes of the impedance circuitry as described above. In some embodiments, the inner electrodes may be positioned near the outer electrodes to increase the voltage of the ECG signal measured by ECG circuitry 138. In some embodiments, the ECG circuitry can share components with the impedance circuitry.



FIG. 1E shows batteries 150 positioned over the flex printed circuit board and electronic components as in FIG. 1D. Batteries 150 may comprise rechargeable batteries that can be removed and/or recharged. In some embodiments, batteries 150 can be removed from the adherent patch and recharged and/or replaced.



FIG. 1F shows a top view of a cover 162 over the batteries, electronic components and flex printed circuit board as in FIG. 1E. In many embodiments, an electronics housing 160 may be disposed under cover 162 to protect the electronic components, and in some embodiments electronics housing 160 may comprise an encapsulant over the electronic components and PCB. In many embodiments, electronics housing 160 may comprise a water proof material, for example a sealant adhesive such as epoxy or silicone coated over the electronics components and/or PCB. In some embodiments, electronics housing 160 may comprise metal and/or plastic, which may be potted with silicone, epoxy, etc.


Cover 162 may comprise many known biocompatible cover, casing and/or housing materials, such as elastomers, for example silicone. The elastomer may be fenestrated to improve breathability. In some embodiments, cover 162 may comprise many known breathable materials, for example polyester or polyamide fabric. The breathable fabric may be coated to make it water resistant, waterproof, and/or to aid in wicking moisture away from the patch. The breathable fabric may be coated in order to make the outside hydrophobic and the inside hydrophilic.



FIG. 1G shows a side view of adherent device 100 as in FIGS. 1A to 1F. Adherent device 100 comprises a maximum dimension, for example a length 170 from about 4 to 10 inches (from about 100 mm to about 250 mm), for example from about 6 to 8 inches (from about 150 mm to about 200 mm). In some embodiments, length 170 may be no more than about 6 inches (no more than about 150 mm). Adherent device 100 comprises a thickness 172. Thickness 172 may comprise a maximum thickness along a profile of the device. Thickness 172 can be from about 0.2 inches to about 0.4 inches (from about 5 mm to about 10 mm), for example about 0.3 inches (about 7.5 mm).



FIG. 1H shown a bottom isometric view of adherent device 100 as in FIGS. 1A to 1G. Adherent device 100 comprises a width 174, for example a maximum width along a width profile of adherent device 100. Width 174 can be from about 2 to about 4 inches (from about 50 mm to 100 mm), for example about 3 inches (about 75 mm).



FIG. 2A shows a method 200 of predicting an impending cardiac decompensation. A step 205 measures an ECG signal. The ECG signal may comprise a differential signal measured with at least two electrodes and may be measured in many known ways. A step 210 measures an hydration signal. The hydration signal may comprise an impedance signal, for example a four pole impedance signal, and may be measured in many known ways. A step 215 measures a respiration signal. The respiration signal may comprise an impedance signal, and may be measured in many known ways. A step 220 measures an activity signal. The activity signal may be measured in many known ways and may comprise a three dimensional accelerometer signal to determine a position of the patient, for example from a three dimensional accelerometer signal. A step 225 measures a temperature signal. The temperature signal may be measured in many ways, for example with a thermistor, a thermocouple, and known temperature measurement devices. A step 230 records a time of day of the signals, for example a local time of day such as morning, afternoon, evening, and/or nighttime.


A step 235 processes the signals. The signals may be processed in many known ways, for example to generate at least one of a derived signal, a time averaged signal, a filtered signal. In some embodiments, the signals may comprise raw signals. The ECG signal may comprise at least one of a heart rate signal, a heart rate variability signal, an average heart rate signal, a maximum heart rate signal or a minimum heart rate signal. The hydration signal may comprise an impedance measurement signal. The activity signal may comprise at least one of an accelerometer signal, a position signal indicating the orientation of the patient, such as standing, lying, or sitting. The respiration signal may comprise a least one of a respiration rate, a maximum respiration rate, a minimum respiration rate, an average respiration rate or respiration rate variability. The temperature may comprise an average temperature or a peak temperature.


A step 240 compares the signals with baseline values. In many embodiments, the baseline values may comprise measurements from the same patient at an earlier time. In some embodiments, the baseline values comprise values for a patient population. In some embodiments, the baseline values for a patient population may comprise empirical data from a suitable patient population size, for example at least about 144 patients, depending on the number of variables measured, statistical confidence and power used. The measured signals may comprise changes and/or deviations from the baseline values.


A step 245 transmits the signals. In many embodiments, the measurement signals, which may comprise derived and/or processed measurement signals, are transmitted to the remote site for comparison. In some embodiments, the signals may be transmitted to a processor supported with the patient for comparison.


A step 250 combines at least two of the ECG signal, the hydration signal, the respiration signal, the activity signal and the temperature signal to detect the impending decompensation. In many embodiments, at least three of the signals are combined. In some embodiments, at least four signals comprising ECG signal, the hydration signal, the respiration signal and the activity signal are combined to detect the impending decompensation. In specific embodiments, at least four signals comprising the ECG signal, the hydration signal, the respiration signal, the activity signal and the temperature signal are combined to detect the impending decompensation.


The signals can be combined in many ways. In some embodiments, the signals can be used simultaneously to determine the impending cardiac decompensation.


In some embodiments, the signals can be combined by using the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal to look up a value in a previously existing array.









TABLE 1







Lookup Table for ECG and Hydration Signals












Heart Rate/Hydration
0-49 bpm
50-69 bpm
70-90 bpm














>60
Ohms
N
N
Y


41-59
Ohms
N
Y
Y


0-40
Ohms
Y
Y
Y









Table 1 shows combination of the electrocardiogram signal with the hydration signal to look up a value in a pre-existing array. For example at a heart rate of 89 bpm and a hydration of 35 Ohms, the value in the table may comprise Y. In specific embodiments, the values of the look up table can be determined in response to empirical data measured for a patient population of at least about 100 patients, for example measurements on about 1000 to 10,000 patients.


In some embodiments, the table may comprise a three or more dimensional look up table.


In some embodiments, the signals may be combined with at least one of adding, subtracting, multiplying, scaling or dividing the at least two of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. In specific embodiments, the measurement signals can be combined with positive and or negative coefficients determined in response to empirical data measured for a patient population of at least about 100 patients, for example data on about 1000 to 10,000 patients.


In some embodiments, a weighted combination may combine at least 3 measurement signals to generate an output value according to a formula of the general form

OUTPUT=aX+bY+cZ

where a, b and c comprise positive or negative coefficients determined from empirical data and X, Y and Z comprise measured signals for the patient, for example at least three of the electrocardiogram signal, the hydration signal, the respiration signal or the activity signal. While three coefficients and three variables are shown, the data may be combined with multiplication and/or division. One or more of the variables may be the inverse of a measured variable.


In some embodiments, the ECG signal comprises a heart rate signal that can be divided by the activity signal. Work in relation to embodiments of the present invention suggest that an increase in heart rate with a decrease in activity can indicate an impending decompensation. The signals can be combined to generate an output value with an equation of the general form

OUTPUT=aX/Y+bZ

where X comprise a heart rate signal, Y comprises a hydration rate signal and Z comprises a respiration signal, with each of the coefficients determined in response to empirical data as described above.


In some embodiments, the data may be combined with a tiered combination. While many tiered combinations can be used a tiered combination with three measurement signals can be expressed as

OUTPUT=(ΔX)+(ΔY)+(ΔZ)

where (ΔX), (ΔY), (ΔZ) may comprise change in heart rate signal from baseline, change in hydration signal from baseline and change in respiration signal from baseline, and each may have a value of zero or one, based on the values of the signals. For example if the heart rate increase by 10%, (ΔX) can be assigned a value of 1. If hydration increases by 5%, (ΔY) can be assigned a value of 1. If activity decreases below 10% of a baseline value (ΔZ) can be assigned a value of 1. When the output signal is three, a flag may be set to trigger an alarm.


In some embodiments, the data may be combined with a logic gated combination. While many logic gated combinations can be used a logic gated combination with three measurement signals can be expressed as

OUTPUT=(ΔX)AND(ΔY)AND(ΔZ)

where (ΔX), (ΔY), (ΔZ) may comprise change in heart rate signal from baseline, change in hydration signal from baseline and change in respiration signal from baseline, and each may have a value of zero or one, based on the values of the signals. For example if the heart rate increase by 10%, (ΔX) can be assigned a value of 1. If hydration increases by 5%, (ΔY) can be assigned a value of 1. If activity decreases below 10% of a baseline value (ΔZ) can be assigned a value of 1. When each of (ΔX), (ΔY), (ΔZ) is one, the output signal is one, and a flag may be set to trigger an alarm. If any one of (ΔX), (ΔY) or (ΔZ) is zero, the output signal is zero and a flag may be set so as not to trigger an alarm. While a specific example with AND gates has been shown the data can be combined in may ways with known gates for example NAND, NOR, OR, NOT, XOR, XNOR gates. In some embodiments, the gated logic may be embodied in a truth table.


A step 255 sets a flag. The flag can be set in response to the output of the combined signals. In some embodiments, the flag may comprise a binary parameter in which a value of zero does not triggers an alarm and a value of one triggers an alarm.


A step 260 communicates with the patient and/or a health care provider. In some embodiments, the remote site may contact the patient to determine if he or she is okay and communicate the impending decompensation such that the patient can receive needed medical care. In some embodiments, the remote site contacts the health care provider to warn the provider of the impending decompensation and the need for the patient to receive medical care.


A step 265 collects additional measurements. Additional measurements may comprise additional measurements with the at least two signals, for example with greater sampling rates and or frequency of the measurements. Additional measurements may comprise measurements with a additional sensors, for example an onboard microphone to detect at least one of rales, S1 heart sounds, S2 heart sounds, S3 heart sounds, or arrhythmias. In some embodiments, the additional measurements, for example sounds, can be transmitted to the health care provider to diagnose the patient in real time.


The processor system, as described above, can be configured to perform the method 200, including many of the steps described above. It should be appreciated that the specific steps illustrated in FIG. 2A provide a particular method of predicting an impending cardiac decompensation, according to an embodiment of the present invention. Other sequences of steps may also be performed according to alternative embodiments. For example, alternative embodiments of the present invention may perform the steps outlined above in a different order. Moreover, the individual steps illustrated in FIG. 2A may include multiple sub-steps that may be performed in various sequences as appropriate to the individual step. Furthermore, additional steps may be added or removed depending on the particular applications. One of ordinary skill in the art would recognize many variations, modifications, and alternatives.


Experimental Clinical Study


The protocol below has been used to measure signals from actual patients with an adherent device. These data show that an adherent patch as described above can be continuously adhered for at least one week. These data also show that 90 day continuous in home monitoring can be achieved with a set of 13 patches in which one of the patches is replaced each week. The clinical testing device used an adherent device with modifications, as described more fully below and referred to as the MS system (multi-sensor). Although the clinical device did not include wireless circuitry and processor circuitry supported with the patch adhered to the skin of the patient, these data do show that such a device, as described above, can be made by one of ordinary skill in the art based on the teachings described herein. Additional empirical studies can be conducted on a suitable number of patients.


MS Clinical System Description


The MS clinical system includes many of the structure components described above. There is a flexible connection between the electrodes and the flex PCB, for example wires or polyurethane with silver ink. The cover can stretch with the breathable tape on both the clinical device and the above described wireless device. There is generally a gap between the flex PCB and breathable tape in both clinical and above described wireless devices. The tested device used weights to at least partially simulate the weight of wireless and processor circuitry. The adherent device of the MS clinical system comprises four electrodes to measure bioimpedance and ECG signals and a 3-axis accelerometer, as described above. Bioimpedance signals were used to determine patient respiration and patient hydration, and accelerometer signals were used to determine patient activity and posture. The MS clinical adherent patch device comprising the sensors and at least some sensor circuitry were connected to a processor to record data. The processor was connected to the tested adherent device with wires and supported away from the tested adherent patch device, for example around the patient's waist. Data were collected at regular intervals and uploaded to a remote site, as described above.


Clinical testing of the MS clinical system shows the effectiveness of the structures for continuous adherence of at least one week and data collection, and that patches can be successively removed and replaced by the patient for in-home monitoring. This effectiveness has been shown without requiring fully functional electronics circuitry such as a battery, wireless circuitry and process circuitry on the adherent device. For example, the MS system includes an insert with about 20 g of additional weight. Although an insert with a 20 gram weight was used for the MS clinical device, greater amounts of weight and circuitry can be used, for example about 30-50 g. The patch device may be modified to accommodate additional weight, for example by increasing the size of the adherent surface. The shape of the MS clinical patch is generally elongate, similar to the elongate shape shown above.


Study Design and Rationale


The MS System is used in a clinical study of heart failure patients to gather data that can be used to develop an algorithm for diagnosing and predicting impending heart failure decompensation events. Events typically manifest as heart failure-related hospitalization, emergency room or urgent care visits leading to a change in oral or IV diuretic treatment.


The purpose of the clinical study is to correlate physiological signals recorded by the system to clinical events of acute heart failure decompensation (AHFD). Signals from the patch can be weighted and combined to determine an index that associates physiologic parameters to impending events of decompensation. Patients who have been classified as New York Heart Association class III and IV within the last 12 months and have had a recent AHFD event can be enrolled into the study and are monitored with the MS system for approximately 90 days.


AHFD events are defined as any of the following:


1) Any heart failure related ER, Urgent Care, in-office visit or hospitalization requiring administration of IV diuretics, administration of IV inotropes, or ultrafiltration for fluid removal.


2) A change in diuretic, defined as a change in diuretic directed by the health care provider occurring inside a hospital, emergency room, or urgent care setting (i.e. no patient self-directed changes to medications not approved by a health care provider would be included), that satisfies one or more of the following: a) a change in the type of diuretic the patient is taking, b) a dose increase of an existing diuretic, or c) the addition of another diuretic.


3) A heart failure decompensation event for which death is the outcome.


Patients enrolled in the study were asked to replace the patch weekly. The study can enroll at least about 550 patients. The patient was provided with a kit comprising 13 patches for replacement. The patches were placed on alternating left and right sides of the patient's thorax, as described above, to minimize progressive irritation.


The data collected in the study can be used to develop an algorithm to at least one of detect, diagnose or predict an impending cardiac decompensation. The algorithm can be implemented on a processor system as described above. Known methods can be used to analyze the data, for example splitting the patients into two groups, one to develop parameters for the algorithm and a second group to test the algorithm developed with the first group. In many embodiments, the signal of the algorithm may comprise a simple binary output for impending cardiac decompensation of the patient. The logic output, yes or no, can be determined in response to patient data combined as described above. The logic output may comprise a signal, such as a binary Y or N signal.


The developed algorithm can be evaluated with composite sensitivity and false positive patient signal status rates. The sensitivity may be defined as the percent of true positive events out of all condition present events, and the false positive patient status signal status rate can be defined as the number of false positive patient status signals per patient-years of follow up. For example, the sensitivity can be at least 50%, for example at least 60%, at least 70%, or even at least 80%. The false positive patient signal status rate may be limited to no more than about 1.1 false positive patient status signals per patient year, for example no more than about 1.0 false positive patient status signals per patient year, no more than about 0.9 false positive patient status signals per patient year, and even no more than about 0.8 false positive patient status signals per patient year.


Clinical Results


Clinical data are available for the first 180 patients enrolled in the study.



FIGS. 3A and 3B show clinical data measured with an adherent patch device, in accordance with the above protocol. FIG. 3A shows data from a patient with the MS patch adhered to a first patient, and the data was acquired over the 90 day period with the series of 13 patches. The signals measured included Heart Rate (beats per minute), Heart Rate Variability (ms), Respiratory Rate (breaths per minute), Activity (m-G's) and Body Fluid (Ohms). FIG. 3B shows data from a second patient similar to FIG. 3A.


Of the 180 patients who have completed the study with the MS adherent patch, as described above, all patches in all patients adhered continuously without patch failure. In all patients, the first patch adhered continuously for the first week. With the exception of a handful of patient deaths and early withdrawals that were unrelated to device failure, all patients reached the end of 90-day follow-up period having used 13 weekly patches without incident. None of the 180 patients showed skin irritation or damage that required withdrawal from the study.


The above data show that the wireless adherent patch device can be constructed for in home wireless patient monitoring for an extended period of at least 90 day, in which each patch of a set is continuously adhered to a patient for at least one week and each patch is configured to support the measurement circuitry, the processor, the wireless communication circuitry and the battery with the skin of the patient.


While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modifications, adaptations, and changes may be employed. Hence, the scope of the present invention should be limited solely by the appended claims.

Claims
  • 1. A system to detect impending acute cardiac decompensation of a patient, the patient having a skin and an extracellular fluid, the system comprising: impedance circuitry to measure, a hydration signal of the patient and a respiration signal of the patient, wherein the hydration signal corresponds to a tissue hydration of the patient; anda processor system comprising a computer readable memory in communication with the impedance circuitry, wherein the computer readable memory of the processor system embodies instructions to combine the hydration signal and the respiration signal to detect the impending acute cardiac decompensation.
  • 2. The system of claim 1 wherein the processor system comprises at least one processor at a location remote from the patient configured to detect impending acute cardiac decompensation.
  • 3. The system of claim 1 wherein the processor system, supported with the patient, receives instructions transmitted from a remote site and combines the hydration signal and the respiration signal in response to the instructions to detect the impending acute cardiac decompensation.
  • 4. The system of claim 1, further comprising circuitry to measure an electrocardiogram signal of the patient, wherein the computer readable memory of the processor system embodies instructions to combine the electrocardiogram signal, the hydration signal, and the respiration signal to detect the impending acute cardiac decompensation.
  • 5. The system of claim 4, further comprising circuitry to measure an activity signal of the patient, wherein the computer readable memory of the processor system embodies instructions to combine the electrocardiogram signal, the hydration signal, the respiration signal and the activity signal to detect the impending acute cardiac decompensation.
  • 6. The system of claim 1 wherein the processor system simultaneously uses the hydration signal and the respiration signal to detect the impending acute cardiac decompensation.
  • 7. The system of claim 1 wherein combing comprises the processor system using the hydration signal and the respiration signal to look up a value in a previously existing array.
  • 8. The system of claim 1 wherein combining comprises at least one of adding, subtracting, multiplying, scaling or dividing the hydration signal and the respiration signal.
  • 9. The system of claim 1 wherein the processor system combines the hydration signal and the respiration signal with at least one of a weighted combination, a tiered combination or a logic gated combination, a time weighted combination or a rate of change.
  • 10. The system of claim 1 wherein the processor system determines a flag status in response to the hydration signal and the respiration signal.
  • 11. The system of claim 8 wherein the processor system determines the flag status in response to a change in the hydration signal and the respiration signal.
  • 12. The system of claim 8 wherein the processor system affects the circuitry to make additional signal measurements of the patient in response to the flag status.
  • 13. The system of claim 1 wherein the processor system combines the hydration signal and the respiration signal in response to a time of day.
  • 14. The system of claim 1 wherein the hydration signal and the respiration signal comprise at least one of a derived signal, a time averaged signal, a filtered signal or a raw signal.
  • 15. The system of claim 1, further comprising an accelerometer to measure an activity signal of the patient, wherein the activity signal is combined with the hydration signal and the respiration signal.
  • 16. The system of claim 1, further comprising circuitry to measure an activity signal of the patient, wherein the activity signal comprises an accelerometer signal to determine a posture of the patient.
  • 17. The system of claim 16 wherein the accelerometer signal comprises a three dimensional inclination signal to determine a three dimensional orientation of the patient.
  • 18. The system of claim 1 wherein the processor transmits the hydration signal and the respiration signal to a remote site where the hydration signal and the respiration signal are combined to detect the impending acute cardiac decompensation.
  • 19. The system of claim 1 wherein the processor system comprises a remote processor located at a site remote from the patient and a processor coupled to a support configured to adhere to the skin of the patient and wherein the remote processor is configured to transmit instructions from the site remote from the patient to the processor coupled to the support, and wherein the processor coupled to the support is configured to combine the hydration signal and the respiration signal in response to the instructions to detect the impending acute cardiac decompensation.
  • 20. The system of claim 1 wherein the circuitry comprises circuitry to measure a skin temperature signal of the patient and wherein the computer readable memory of the processor system embodies instructions to correct the hydration signal such that the hydration signal remains substantially unchanged when the measured impedance decreases and the skin temperature increases.
  • 21. The system of claim 1 wherein the patient exhibits heart failure corresponding to a New York Heart Association classification of class III and wherein the computer readable memory embodies instructions to detect the impending acute cardiac decompensation with a sensitivity of at least about 50% and a false positive patient status signal rate of no more than about 1.1 false positive patient status signals per patient year.
  • 22. The system of claim 1 wherein the hydration signal of the patient and the respiration signal of the patient are based on impedance measurements made at a single frequency within a range from about 0.5 kHz to about 20 kHz to determine a tissue impedance.
  • 23. The system of claim 1 wherein the hydration signal of the patient and the respiration signal of the patient are based on impedance measurements made at a single frequency within a range from about 0.5 kHz to about 10 kHz to determine a tissue impedance.
  • 24. The system of claim 1 wherein the computer readable memory embodies instructions to determine the change of the hydration signal based on a baseline hydration value of the patient measured at least one week before the hydration signal and instructions to determine the change of the respiration signal based on a baseline respirations value of the patient measured at least one week before the respiration signal.
  • 25. The system of claim 1 wherein the computer readable memory embodies instructions to determine the change of the hydration signal based on a baseline hydration value of the patient measured with a first adherent device at least one week before the hydration signal measured with a second adherent device and instructions to determine the change of the respiration signal based on a baseline respiration value of the patient measured with the first adherent device at least one week before the respiration signal measured with the second adherent device.
  • 26. A system to predict an impending acute cardiac decompensation of a patient having heart failure, the patient having a skin and extracellular fluid, the system comprising: circuitry to measure an activity signal of the patient, a hydration signal of the patient and a respiration signal of the patient, the circuitry comprising an accelerometer to measure the activity signal of the patient, the circuitry comprising impedance circuitry to measure the hydration signal of the patient and the respiration signal of the patient based on impedance measurements, the impedance measurements having a single frequency within a range from about 1 kHz to about 10 kHz such that the hydration signal corresponds to a tissue hydration of the patient; anda processor system comprising a computer readable memory in communication with the circuitry, wherein the computer readable memory of the processor system embodies instructions to combine the hydration signal and the respirations signal to predict the impending acute cardiac decompensation, wherein the computer readable memory embodies instructions to determine a baseline hydration value of the patient and compare the baseline hydration value to the hydration signal to determine a change of the hydration signal from the baseline hydration value over a 90 day period and instructions to determine a baseline respiration value of the patient and compare the baseline respiration value to the respiration signal over the 90 day period to determine a change of the respiration signal from the baseline respiration value and wherein the processor system embodies instructions to predict the impending acute cardiac decopmensation based on the change of the hydration signal and the change of the respiration signal.
  • 27. The system of claim 1, wherein the computer readable memory embodies instructions to determine a baseline hydration value of the patient and compare the baseline hydration value to the hydration signal to determine a change of the hydration signal from the baseline hydration value and instructions to detect the impending acute cardiac decompensation based in part on the change of the hydration signal.
  • 28. A system to detect impending acute cardiac decompensation of a patient, the system comprising: impedance circuitry to measure a hydration signal of the patient such that the hydration signal corresponds to a tissue hydration of the patient, wherein a respiration signal of the patient is derived from the impedance circuitry; anda processor system in communication with the impedance circuitry, the processor system comprising a computer readable memory storing instructions to detect the impending acute cardiac decompensation based at least in part on the hydration signal of the patient and the respiration signal of the patient.
  • 29. The system of claim 28, wherein the computer readable memory stores instructions to determine a baseline hydration value of the patient and compare the baseline hydration value to the hydration signal to determine a change of the hydration signal from the baseline hydration value and instructions to detect the impending acute cardiac decompensation based at least in part on the change of the hydration signal.
  • 30. The system of claim 29, wherein the hydration signal is based on impedance measurements having a frequency within a range from about 0.5 kHz to about 20 kHz.
  • 31. The system of claim 28, wherein the computer readable memory stores instructions to determine a baseline respiration value of the patient and compare the baseline respiration value to the respiration signal to determine a change of the respiration signal from the baseline respiration value and instructions to detect the impending acute cardiac decompensation based in part on the change of the respiration signal.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application claims the benefit under 35 USC 119(e) of U.S. Provisional Application Nos. 60/972,512 and 60/972,537 both filed Sep. 14, 2007, and 61/055,666 filed May 23, 2008; the full disclosures of which are incorporated herein by reference in their entirety.

US Referenced Citations (745)
Number Name Date Kind
834261 Chambers Oct 1906 A
2087124 Smith et al. Jul 1937 A
2184511 Bagno et al. Dec 1939 A
3170459 Phipps et al. Feb 1965 A
3232291 Parker Feb 1966 A
3370459 Cescati Feb 1968 A
3517999 Weaver Jun 1970 A
3620216 Szymanski Nov 1971 A
3677260 Funfstuck et al. Jul 1972 A
3805769 Sessions Apr 1974 A
3845757 Weyer Nov 1974 A
3874368 Asrican Apr 1975 A
3882853 Gofman et al. May 1975 A
3942517 Bowles et al. Mar 1976 A
3972329 Kaufman Aug 1976 A
4008712 Nyboer Feb 1977 A
4024312 Korpman May 1977 A
4077406 Sandhage et al. Mar 1978 A
4121573 Crovella et al. Oct 1978 A
4141366 Cross, Jr. et al. Feb 1979 A
RE30101 Kubicek et al. Sep 1979 E
4185621 Morrow Jan 1980 A
4216462 McGrath et al. Aug 1980 A
4300575 Wilson Nov 1981 A
4308872 Watson et al. Jan 1982 A
4358678 Lawrence Nov 1982 A
4409983 Albert Oct 1983 A
4450527 Sramek May 1984 A
4451254 Dinius et al. May 1984 A
4478223 Allor Oct 1984 A
4498479 Martio et al. Feb 1985 A
4522211 Bare et al. Jun 1985 A
4661103 Harman Apr 1987 A
4664129 Helzel et al. May 1987 A
4669480 Hoffman Jun 1987 A
4673387 Phillips et al. Jun 1987 A
4681118 Asai et al. Jul 1987 A
4692685 Blaze Sep 1987 A
4699146 Sieverding Oct 1987 A
4721110 Lampadius Jan 1988 A
4730611 Lamb Mar 1988 A
4733107 O'Shaughnessy et al. Mar 1988 A
4781200 Baker Nov 1988 A
4793362 Tedner Dec 1988 A
4838273 Cartmell Jun 1989 A
4838279 Fore Jun 1989 A
4850370 Dower Jul 1989 A
4880004 Baker, Jr. et al. Nov 1989 A
4895163 Libke et al. Jan 1990 A
4911175 Shizgal Mar 1990 A
4945916 Kretschmer et al. Aug 1990 A
4955381 Way et al. Sep 1990 A
4966158 Honma et al. Oct 1990 A
4981139 Pfohl Jan 1991 A
4988335 Prindle et al. Jan 1991 A
4989612 Fore Feb 1991 A
5001632 Hall-Tipping Mar 1991 A
5012810 Strand et al. May 1991 A
5025791 Niwa Jun 1991 A
5027824 Dougherty et al. Jul 1991 A
5050612 Matsumura Sep 1991 A
5063937 Ezenwa et al. Nov 1991 A
5080099 Way et al. Jan 1992 A
5083563 Collins Jan 1992 A
5086781 Bookspan Feb 1992 A
5113869 Nappholz et al. May 1992 A
5125412 Thornton Jun 1992 A
5133355 Strand et al. Jul 1992 A
5140985 Schroeder et al. Aug 1992 A
5150708 Brooks Sep 1992 A
5168874 Segalowitz Dec 1992 A
5226417 Swedlow et al. Jul 1993 A
5241300 Buschmann Aug 1993 A
5257627 Rapoport Nov 1993 A
5271411 Ripley et al. Dec 1993 A
5273532 Niezink et al. Dec 1993 A
5282840 Hudrlik Feb 1994 A
5291013 Nafarrate et al. Mar 1994 A
5297556 Shankar Mar 1994 A
5301677 Hsung Apr 1994 A
5319363 Welch et al. Jun 1994 A
5331966 Bennett et al. Jul 1994 A
5335664 Nagashima Aug 1994 A
5343869 Pross et al. Sep 1994 A
5353793 Bornn Oct 1994 A
5362069 Hall-Tipping Nov 1994 A
5375604 Kelly et al. Dec 1994 A
5411530 Akhtar May 1995 A
5437285 Verrier et al. Aug 1995 A
5443073 Wang et al. Aug 1995 A
5449000 Libke et al. Sep 1995 A
5450845 Axelgaard Sep 1995 A
5454377 Dzwonczyk et al. Oct 1995 A
5464012 Falcone Nov 1995 A
5469859 Tsoglin et al. Nov 1995 A
5482036 Diab et al. Jan 1996 A
5496361 Moberg et al. Mar 1996 A
5503157 Sramek Apr 1996 A
5511548 Riazzi et al. Apr 1996 A
5511553 Segalowitz Apr 1996 A
5518001 Snell May 1996 A
5523742 Simkins et al. Jun 1996 A
5529072 Sramek Jun 1996 A
5544661 Davis et al. Aug 1996 A
5558638 Evers et al. Sep 1996 A
5560368 Berger Oct 1996 A
5564429 Bornn et al. Oct 1996 A
5564434 Halperin et al. Oct 1996 A
5566671 Lyons Oct 1996 A
5575284 Athan et al. Nov 1996 A
5607454 Cameron et al. Mar 1997 A
5632272 Diab et al. May 1997 A
5634468 Platt et al. Jun 1997 A
5642734 Ruben et al. Jul 1997 A
5673704 Marchlinski et al. Oct 1997 A
5678562 Sellers Oct 1997 A
5687717 Halpern et al. Nov 1997 A
5710376 Weber Jan 1998 A
5718234 Warden et al. Feb 1998 A
5724025 Tavori Mar 1998 A
5738107 Martinsen et al. Apr 1998 A
5748103 Flach et al. May 1998 A
5767791 Stoop et al. Jun 1998 A
5769793 Pincus et al. Jun 1998 A
5772508 Sugita et al. Jun 1998 A
5772586 Heinonen et al. Jun 1998 A
5778882 Raymond et al. Jul 1998 A
5788643 Feldman Aug 1998 A
5788682 Maget Aug 1998 A
5803915 Kremenchugsky et al. Sep 1998 A
5807272 Kun Sep 1998 A
5814079 Kieval et al. Sep 1998 A
5817035 Sullivan Oct 1998 A
5833603 Kovacs et al. Nov 1998 A
5836990 Li Nov 1998 A
5855614 Stevens et al. Jan 1999 A
5860860 Clayman Jan 1999 A
5862802 Bird Jan 1999 A
5862803 Besson et al. Jan 1999 A
5865733 Malinouskas et al. Feb 1999 A
5876353 Riff Mar 1999 A
5904708 Goedeke May 1999 A
5935079 Swanson et al. Aug 1999 A
5941831 Turcott Aug 1999 A
5944659 Flach et al. Aug 1999 A
5949636 Johnson et al. Sep 1999 A
5957854 Besson et al. Sep 1999 A
5957861 Combs et al. Sep 1999 A
5964703 Goodman et al. Oct 1999 A
5970986 Bolz et al. Oct 1999 A
5984102 Tay Nov 1999 A
5987352 Klein et al. Nov 1999 A
6007532 Netherly Dec 1999 A
6027523 Schmieding Feb 2000 A
6045513 Stone et al. Apr 2000 A
6047203 Sackner et al. Apr 2000 A
6047259 Campbell et al. Apr 2000 A
6049730 Kristbjarnarson Apr 2000 A
6050267 Nardella et al. Apr 2000 A
6050951 Friedman et al. Apr 2000 A
6052615 Feild et al. Apr 2000 A
6067467 John May 2000 A
6080106 Lloyd et al. Jun 2000 A
6081735 Diab et al. Jun 2000 A
6095991 Krausman et al. Aug 2000 A
6102856 Groff et al. Aug 2000 A
6104949 Pitts Crick et al. Aug 2000 A
6112224 Peifer et al. Aug 2000 A
6117077 Del Mar et al. Sep 2000 A
6125297 Siconolfi Sep 2000 A
6129744 Boute Oct 2000 A
6141575 Price Oct 2000 A
6144878 Schroeppel et al. Nov 2000 A
6164284 Schulman et al. Dec 2000 A
6181963 Chin et al. Jan 2001 B1
6185452 Schulman et al. Feb 2001 B1
6190313 Hinkle Feb 2001 B1
6190324 Kieval et al. Feb 2001 B1
6198394 Jacobsen et al. Mar 2001 B1
6198955 Axelgaard et al. Mar 2001 B1
6208894 Schulman et al. Mar 2001 B1
6212427 Hoover Apr 2001 B1
6213942 Flach et al. Apr 2001 B1
6225901 Kail, IV May 2001 B1
6245021 Stampfer Jun 2001 B1
6259939 Rogel Jul 2001 B1
6267730 Pacunas Jul 2001 B1
6272377 Sweeney et al. Aug 2001 B1
6277078 Porat et al. Aug 2001 B1
6287252 Lugo Sep 2001 B1
6289238 Besson et al. Sep 2001 B1
6290646 Cosentino et al. Sep 2001 B1
6295466 Ishikawa et al. Sep 2001 B1
6305943 Pougatchev et al. Oct 2001 B1
6306088 Krausman et al. Oct 2001 B1
6308094 Shusterman et al. Oct 2001 B1
6312378 Bardy Nov 2001 B1
6315721 Schulman et al. Nov 2001 B2
6327487 Stratbucker Dec 2001 B1
6330464 Colvin et al. Dec 2001 B1
6336903 Bardy Jan 2002 B1
6339722 Heethaar et al. Jan 2002 B1
6343140 Brooks Jan 2002 B1
6347245 Lee et al. Feb 2002 B1
6358208 Lang et al. Mar 2002 B1
6385473 Haines et al. May 2002 B1
6398727 Bui et al. Jun 2002 B1
6400982 Sweeney et al. Jun 2002 B2
6409674 Brockway et al. Jun 2002 B1
6411853 Millot et al. Jun 2002 B1
6416471 Kumar et al. Jul 2002 B1
6440069 Raymond et al. Aug 2002 B1
6442422 Duckert Aug 2002 B1
6450820 Palsson et al. Sep 2002 B1
6450953 Place et al. Sep 2002 B1
6453186 Lovejoy et al. Sep 2002 B1
6454707 Casscells, III et al. Sep 2002 B1
6454708 Ferguson et al. Sep 2002 B1
6463328 John Oct 2002 B1
6473640 Erlebacher Oct 2002 B1
6480733 Turcott Nov 2002 B1
6480734 Zhang et al. Nov 2002 B1
6485461 Mason et al. Nov 2002 B1
6490478 Zhang et al. Dec 2002 B1
6491647 Bridger et al. Dec 2002 B1
6494829 New, Jr. et al. Dec 2002 B1
6496715 Lee et al. Dec 2002 B1
6512949 Combs et al. Jan 2003 B1
6520967 Cauthen Feb 2003 B1
6527711 Stivoric et al. Mar 2003 B1
6527729 Turcott Mar 2003 B1
6528960 Roden et al. Mar 2003 B1
6544173 West et al. Apr 2003 B2
6544174 West et al. Apr 2003 B2
6551251 Zuckerwar et al. Apr 2003 B2
6551252 Sackner et al. Apr 2003 B2
6569160 Goldin et al. May 2003 B1
6572557 Tchou et al. Jun 2003 B2
6572636 Hagen et al. Jun 2003 B1
6577139 Cooper Jun 2003 B2
6577893 Besson et al. Jun 2003 B1
6577897 Shurubura et al. Jun 2003 B1
6579231 Phipps Jun 2003 B1
6580942 Willshire Jun 2003 B1
6584343 Ransbury et al. Jun 2003 B1
6587715 Singer Jul 2003 B2
6589170 Flach et al. Jul 2003 B1
6595927 Pitts-Crick et al. Jul 2003 B2
6595929 Stivoric et al. Jul 2003 B2
6600949 Turcott Jul 2003 B1
6602201 Malecha et al. Aug 2003 B1
6605038 Teller et al. Aug 2003 B1
6611705 Hopman et al. Aug 2003 B2
6611783 Kelly et al. Aug 2003 B2
6616606 Petersen et al. Sep 2003 B1
6622042 Thacker Sep 2003 B1
6636754 Baura et al. Oct 2003 B1
6641542 Cho et al. Nov 2003 B2
6645153 Kroll et al. Nov 2003 B2
6649829 Garber et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6658300 Govari et al. Dec 2003 B2
6659947 Carter et al. Dec 2003 B1
6659949 Lang et al. Dec 2003 B1
6687540 Marcovecchio Feb 2004 B2
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699200 Cao et al. Mar 2004 B2
6701271 Willner et al. Mar 2004 B2
6714813 Ishigooka et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6721594 Conley et al. Apr 2004 B2
6728572 Hsu et al. Apr 2004 B2
6748269 Thompson et al. Jun 2004 B2
6749566 Russ Jun 2004 B2
6751498 Greenberg et al. Jun 2004 B1
6760617 Ward et al. Jul 2004 B2
6773396 Flach et al. Aug 2004 B2
6775566 Nissila Aug 2004 B2
6790178 Mault et al. Sep 2004 B1
6795722 Sheraton et al. Sep 2004 B2
6814706 Barton et al. Nov 2004 B2
6816744 Garfield et al. Nov 2004 B2
6821249 Casscells, III et al. Nov 2004 B2
6824515 Suorsa et al. Nov 2004 B2
6827690 Bardy Dec 2004 B2
6829503 Alt Dec 2004 B2
6858006 MacCarter et al. Feb 2005 B2
6871211 Labounty et al. Mar 2005 B2
6878121 Krausman et al. Apr 2005 B2
6879850 Kimball Apr 2005 B2
6881191 Oakley et al. Apr 2005 B2
6887201 Bardy May 2005 B2
6890096 Tokita et al. May 2005 B2
6893396 Schulze et al. May 2005 B2
6894204 Dunshee May 2005 B2
6906530 Geisel Jun 2005 B2
6912414 Tong Jun 2005 B2
6936006 Sabra Aug 2005 B2
6940403 Kail, IV Sep 2005 B2
6942622 Turcott Sep 2005 B1
6952695 Trinks et al. Oct 2005 B1
6970742 Mann et al. Nov 2005 B2
6972683 Lestienne et al. Dec 2005 B2
6978177 Chen et al. Dec 2005 B1
6980851 Zhu et al. Dec 2005 B2
6980852 Jersey-Willuhn et al. Dec 2005 B2
6985078 Suzuki et al. Jan 2006 B2
6987965 Ng et al. Jan 2006 B2
6988989 Weiner et al. Jan 2006 B2
6993378 Wiederhold et al. Jan 2006 B2
6997879 Turcott Feb 2006 B1
7003346 Singer Feb 2006 B2
7009362 Tsukamoto et al. Mar 2006 B2
7010340 Scarantino et al. Mar 2006 B2
7018338 Vetter et al. Mar 2006 B2
7020508 Stivoric et al. Mar 2006 B2
7027862 Dahl et al. Apr 2006 B2
7041062 Friedrichs et al. May 2006 B2
7044911 Drinan et al. May 2006 B2
7047067 Gray et al. May 2006 B2
7050846 Sweeney et al. May 2006 B2
7054679 Hirsh May 2006 B2
7059767 Tokita et al. Jun 2006 B2
7088242 Aupperle et al. Aug 2006 B2
7113826 Henry et al. Sep 2006 B2
7118531 Krill Oct 2006 B2
7127370 Kelly, Jr. et al. Oct 2006 B2
7129836 Lawson et al. Oct 2006 B2
7130396 Rogers et al. Oct 2006 B2
7130679 Parsonnet et al. Oct 2006 B2
7133716 Kraemer et al. Nov 2006 B2
7136697 Singer Nov 2006 B2
7136703 Cappa et al. Nov 2006 B1
7142907 Xue et al. Nov 2006 B2
7149574 Yun et al. Dec 2006 B2
7149773 Haller et al. Dec 2006 B2
7153262 Stivoric et al. Dec 2006 B2
7156807 Carter et al. Jan 2007 B2
7156808 Quy Jan 2007 B2
7160252 Cho et al. Jan 2007 B2
7160253 Nissila Jan 2007 B2
7166063 Rahman et al. Jan 2007 B2
7167743 Heruth et al. Jan 2007 B2
7184821 Belalcazar et al. Feb 2007 B2
7191000 Zhu et al. Mar 2007 B2
7194306 Turcott Mar 2007 B1
7206630 Tarler Apr 2007 B1
7212849 Zhang et a May 2007 B2
7215984 Diab et al. May 2007 B2
7215991 Besson et al. May 2007 B2
7238159 Banet et al. Jul 2007 B2
7248916 Bardy Jul 2007 B2
7251524 Hepp et al. Jul 2007 B1
7257438 Kinast Aug 2007 B2
7261690 Teller et al. Aug 2007 B2
7277741 Debreczeny et al. Oct 2007 B2
7284904 Tokita et al. Oct 2007 B2
7285090 Stivoric et al. Oct 2007 B2
7294105 Islam Nov 2007 B1
7295879 Denker et al. Nov 2007 B2
7297119 Westbrook et al. Nov 2007 B2
7318808 Tarassenko et al. Jan 2008 B2
7319386 Collins, Jr. et al. Jan 2008 B2
7336187 Hubbard, Jr. et al. Feb 2008 B2
7346380 Axelgaard et al. Mar 2008 B2
7382247 Welch et al. Jun 2008 B2
7384398 Gagnadre et al. Jun 2008 B2
7390299 Weiner et al. Jun 2008 B2
7395106 Ryu et al. Jul 2008 B2
7423526 Despotis Sep 2008 B2
7423537 Bonnet et al. Sep 2008 B2
7443302 Reeder et al. Oct 2008 B2
7450024 Wildman et al. Nov 2008 B2
7468032 Stahmann et al. Dec 2008 B2
7510699 Black et al. Mar 2009 B2
7660632 Kirby et al. Feb 2010 B2
7701227 Saulnier et al. Apr 2010 B2
7813778 Benaron et al. Oct 2010 B2
7881763 Brauker et al. Feb 2011 B2
7942824 Kayyali et al. May 2011 B1
8248686 Kwon et al. Aug 2012 B2
8285356 Bly et al. Oct 2012 B2
20010047127 New, Jr. et al. Nov 2001 A1
20020004640 Conn et al. Jan 2002 A1
20020019586 Teller et al. Feb 2002 A1
20020019588 Marro et al. Feb 2002 A1
20020022786 Takehara et al. Feb 2002 A1
20020028989 Pelletier et al. Mar 2002 A1
20020032581 Reitberg Mar 2002 A1
20020045836 Alkawwas Apr 2002 A1
20020088465 Hill Jul 2002 A1
20020099277 Harry et al. Jul 2002 A1
20020116009 Fraser et al. Aug 2002 A1
20020123672 Christophersom et al. Sep 2002 A1
20020123674 Plicchi et al. Sep 2002 A1
20020138017 Bui et al. Sep 2002 A1
20020167389 Uchikoba et al. Nov 2002 A1
20020182485 Anderson et al. Dec 2002 A1
20030009092 Parker Jan 2003 A1
20030023184 Pitts-Crick et al. Jan 2003 A1
20030028221 Zhu et al. Feb 2003 A1
20030028327 Brunner et al. Feb 2003 A1
20030045922 Northrop Mar 2003 A1
20030051144 Williams Mar 2003 A1
20030055460 Owen et al. Mar 2003 A1
20030069510 Semler Apr 2003 A1
20030083581 Taha et al. May 2003 A1
20030085717 Cooper May 2003 A1
20030087244 McCarthy May 2003 A1
20030092975 Casscells, III et al. May 2003 A1
20030093125 Zhu et al. May 2003 A1
20030093298 Hernandez et al. May 2003 A1
20030100367 Cooke May 2003 A1
20030105411 Smallwood et al. Jun 2003 A1
20030135127 Sackner et al. Jul 2003 A1
20030143544 McCarthy Jul 2003 A1
20030149349 Jensen Aug 2003 A1
20030181815 Ebner et al. Sep 2003 A1
20030187370 Kodama Oct 2003 A1
20030191503 Zhu et al. Oct 2003 A1
20030212319 Magill Nov 2003 A1
20030221687 Kaigler Dec 2003 A1
20030233129 Matos Dec 2003 A1
20040006279 Arad (Abboud) Jan 2004 A1
20040010303 Bolea et al. Jan 2004 A1
20040014422 Kallio Jan 2004 A1
20040015058 Besson et al. Jan 2004 A1
20040019292 Drinan et al. Jan 2004 A1
20040044293 Burton Mar 2004 A1
20040049132 Barron et al. Mar 2004 A1
20040064133 Miller et al. Apr 2004 A1
20040073094 Baker Apr 2004 A1
20040073126 Rowlandson Apr 2004 A1
20040077954 Oakley et al. Apr 2004 A1
20040100376 Lye et al. May 2004 A1
20040102683 Khanuja et al. May 2004 A1
20040106951 Edman et al. Jun 2004 A1
20040122489 Mazar et al. Jun 2004 A1
20040127790 Lang et al. Jul 2004 A1
20040133079 Mazar et al. Jul 2004 A1
20040133081 Teller et al. Jul 2004 A1
20040134496 Cho et al. Jul 2004 A1
20040143170 DuRousseau Jul 2004 A1
20040147969 Mann et al. Jul 2004 A1
20040152956 Korman Aug 2004 A1
20040158132 Zaleski Aug 2004 A1
20040167389 Brabrand Aug 2004 A1
20040172080 Stadler et al. Sep 2004 A1
20040199056 Husemann et al. Oct 2004 A1
20040215240 Lovett et al. Oct 2004 A1
20040215247 Bolz Oct 2004 A1
20040220639 Mulligan et al. Nov 2004 A1
20040225199 Evanyk et al. Nov 2004 A1
20040225203 Jemison et al. Nov 2004 A1
20040243018 Organ et al. Dec 2004 A1
20040267142 Paul Dec 2004 A1
20050004506 Gyory Jan 2005 A1
20050015094 Keller Jan 2005 A1
20050015095 Keller Jan 2005 A1
20050020935 Helzel et al. Jan 2005 A1
20050027175 Yang Feb 2005 A1
20050027204 Kligfield et al. Feb 2005 A1
20050027207 Westbrook et al. Feb 2005 A1
20050027918 Govindarajulu et al. Feb 2005 A1
20050043675 Pastore et al. Feb 2005 A1
20050054944 Nakada et al. Mar 2005 A1
20050059867 Chung Mar 2005 A1
20050065445 Arzbaecher et al. Mar 2005 A1
20050065571 Imran Mar 2005 A1
20050070768 Zhu et al. Mar 2005 A1
20050070778 Lackey et al. Mar 2005 A1
20050080346 Gianchandani et al. Apr 2005 A1
20050080460 Wang et al. Apr 2005 A1
20050080463 Stahmann et al. Apr 2005 A1
20050085734 Tehrani Apr 2005 A1
20050091338 de la Huerga Apr 2005 A1
20050096513 Ozguz et al. May 2005 A1
20050113703 Farringdon et al. May 2005 A1
20050124878 Sharony Jun 2005 A1
20050124901 Misczynski et al. Jun 2005 A1
20050124908 Belalcazar et al. Jun 2005 A1
20050131288 Turner et al. Jun 2005 A1
20050137464 Bomba Jun 2005 A1
20050137626 Pastore et al. Jun 2005 A1
20050148895 Misczynski et al. Jul 2005 A1
20050158539 Murphy et al. Jul 2005 A1
20050177038 Kolpin et al. Aug 2005 A1
20050187482 O'Brien et al. Aug 2005 A1
20050187796 Rosenfeld et al. Aug 2005 A1
20050192488 Bryenton et al. Sep 2005 A1
20050197654 Edman et al. Sep 2005 A1
20050203433 Singer Sep 2005 A1
20050203435 Nakada Sep 2005 A1
20050203436 Davies Sep 2005 A1
20050203637 Edman et al. Sep 2005 A1
20050206518 Welch et al. Sep 2005 A1
20050215914 Bornzin et al. Sep 2005 A1
20050215918 Frantz et al. Sep 2005 A1
20050228234 Yang Oct 2005 A1
20050228238 Monitzer Oct 2005 A1
20050228244 Banet Oct 2005 A1
20050239493 Batkin et al. Oct 2005 A1
20050240087 Keenan et al. Oct 2005 A1
20050251044 Hoctor et al. Nov 2005 A1
20050256418 Mietus et al. Nov 2005 A1
20050261598 Banet et al. Nov 2005 A1
20050261743 Kroll Nov 2005 A1
20050267376 Marossero et al. Dec 2005 A1
20050267377 Marossero et al. Dec 2005 A1
20050267381 Benditt et al. Dec 2005 A1
20050273023 Bystrom et al. Dec 2005 A1
20050277841 Shennib Dec 2005 A1
20050277842 Silva Dec 2005 A1
20050277992 Koh et al. Dec 2005 A1
20050280531 Fadem et al. Dec 2005 A1
20050283197 Daum et al. Dec 2005 A1
20050288601 Wood et al. Dec 2005 A1
20060004300 Kennedy Jan 2006 A1
20060004377 Keller Jan 2006 A1
20060009697 Banet et al. Jan 2006 A1
20060009701 Nissila et al. Jan 2006 A1
20060010090 Brockway et al. Jan 2006 A1
20060020218 Freeman et al. Jan 2006 A1
20060025661 Sweeney et al. Feb 2006 A1
20060030781 Shennib Feb 2006 A1
20060030782 Shennib Feb 2006 A1
20060031102 Teller et al. Feb 2006 A1
20060041280 Stahmann et al. Feb 2006 A1
20060047215 Newman et al. Mar 2006 A1
20060052678 Drinan et al. Mar 2006 A1
20060058543 Walter et al. Mar 2006 A1
20060058593 Drinan et al. Mar 2006 A1
20060064030 Cosentino et al. Mar 2006 A1
20060064040 Berger et al. Mar 2006 A1
20060064142 Chavan et al. Mar 2006 A1
20060066449 Johnson Mar 2006 A1
20060074283 Henderson et al. Apr 2006 A1
20060074462 Verhoef Apr 2006 A1
20060075257 Martis et al. Apr 2006 A1
20060084881 Korzinov et al. Apr 2006 A1
20060085049 Cory et al. Apr 2006 A1
20060089679 Zhu et al. Apr 2006 A1
20060094948 Gough et al. May 2006 A1
20060102476 Niwa et al. May 2006 A1
20060116592 Zhou et al. Jun 2006 A1
20060122474 Teller et al. Jun 2006 A1
20060135858 Nidd et al. Jun 2006 A1
20060142654 Rytky Jun 2006 A1
20060142820 Von Arx et al. Jun 2006 A1
20060149168 Czarnek Jul 2006 A1
20060155174 Glukhovsky et al. Jul 2006 A1
20060155183 Kroecker et al. Jul 2006 A1
20060155200 Ng Jul 2006 A1
20060157893 Patel Jul 2006 A1
20060161073 Singer Jul 2006 A1
20060161205 Mitrani et al. Jul 2006 A1
20060161459 Rosenfeld et al. Jul 2006 A9
20060167374 Takehara et al. Jul 2006 A1
20060173257 Nagai et al. Aug 2006 A1
20060173269 Glossop Aug 2006 A1
20060195020 Martin et al. Aug 2006 A1
20060195039 Drew et al. Aug 2006 A1
20060195097 Evans et al. Aug 2006 A1
20060195144 Giftakis et al. Aug 2006 A1
20060202816 Crump et al. Sep 2006 A1
20060212097 Varadan et al. Sep 2006 A1
20060224051 Teller et al. Oct 2006 A1
20060224072 Shennib Oct 2006 A1
20060224079 Washchuk Oct 2006 A1
20060235281 Tuccillo Oct 2006 A1
20060235316 Ungless et al. Oct 2006 A1
20060235489 Drew et al. Oct 2006 A1
20060241641 Albans et al. Oct 2006 A1
20060241701 Markowitz et al. Oct 2006 A1
20060241722 Thacker et al. Oct 2006 A1
20060247545 St. Martin Nov 2006 A1
20060252999 Devaul et al. Nov 2006 A1
20060253005 Drinan et al. Nov 2006 A1
20060253044 Zhang et al. Nov 2006 A1
20060258952 Stahmann et al. Nov 2006 A1
20060264730 Stivoric et al. Nov 2006 A1
20060264767 Shennib Nov 2006 A1
20060264776 Stahmann et al. Nov 2006 A1
20060271116 Stahmann et al. Nov 2006 A1
20060276714 Holt et al. Dec 2006 A1
20060281981 Jang et al. Dec 2006 A1
20060281996 Kuo et al. Dec 2006 A1
20060293571 Bao et al. Dec 2006 A1
20060293609 Stahmann et al. Dec 2006 A1
20070010721 Chen et al. Jan 2007 A1
20070010750 Ueno et al. Jan 2007 A1
20070015973 Nanikashvili Jan 2007 A1
20070015976 Miesel et al. Jan 2007 A1
20070016089 Fischell et al. Jan 2007 A1
20070021678 Beck et al. Jan 2007 A1
20070021790 Kieval et al. Jan 2007 A1
20070021792 Kieval et al. Jan 2007 A1
20070021794 Kieval et al. Jan 2007 A1
20070021796 Kieval et al. Jan 2007 A1
20070021797 Kieval et al. Jan 2007 A1
20070021798 Kieval et al. Jan 2007 A1
20070021799 Kieval et al. Jan 2007 A1
20070027388 Chou Feb 2007 A1
20070027497 Parnis Feb 2007 A1
20070032749 Overall et al. Feb 2007 A1
20070038038 Stivoric et al. Feb 2007 A1
20070038078 Osadchy Feb 2007 A1
20070038255 Kieval et al. Feb 2007 A1
20070038262 Kieval et al. Feb 2007 A1
20070043301 Martinsen et al. Feb 2007 A1
20070043303 Osypka et al. Feb 2007 A1
20070043394 Zhang et al. Feb 2007 A1
20070048224 Howell et al. Mar 2007 A1
20070060800 Drinan et al. Mar 2007 A1
20070060802 Ghevondian et al. Mar 2007 A1
20070073132 Vosch Mar 2007 A1
20070073168 Zhang et al. Mar 2007 A1
20070073169 Averina et al. Mar 2007 A1
20070073181 Pu et al. Mar 2007 A1
20070073361 Goren et al. Mar 2007 A1
20070082189 Gillette Apr 2007 A1
20070083092 Rippo et al. Apr 2007 A1
20070092862 Gerber Apr 2007 A1
20070104840 Singer May 2007 A1
20070106132 Elhag et al. May 2007 A1
20070106137 Baker, Jr. et al. May 2007 A1
20070106167 Kinast May 2007 A1
20070118039 Bodecker et al. May 2007 A1
20070123756 Kitajima et al. May 2007 A1
20070123903 Raymond et al. May 2007 A1
20070123904 Stad et al. May 2007 A1
20070129622 Bourget et al. Jun 2007 A1
20070129643 Kwok et al. Jun 2007 A1
20070129769 Bourget et al. Jun 2007 A1
20070142715 Banet et al. Jun 2007 A1
20070142732 Brockway et al. Jun 2007 A1
20070149282 Lu et al. Jun 2007 A1
20070150008 Jones et al. Jun 2007 A1
20070150009 Kveen et al. Jun 2007 A1
20070150029 Bourget et al. Jun 2007 A1
20070162089 Mosesov Jul 2007 A1
20070167753 Van Wyk et al. Jul 2007 A1
20070167848 Kuo et al. Jul 2007 A1
20070167849 Zhang et al. Jul 2007 A1
20070167850 Russell et al. Jul 2007 A1
20070172424 Roser Jul 2007 A1
20070173705 Teller et al. Jul 2007 A1
20070180047 Dong et al. Aug 2007 A1
20070180140 Welch et al. Aug 2007 A1
20070191723 Prystowsky et al. Aug 2007 A1
20070207858 Breving Sep 2007 A1
20070208233 Kovacs Sep 2007 A1
20070208235 Besson et al. Sep 2007 A1
20070208262 Kovacs Sep 2007 A1
20070232867 Hansmann Oct 2007 A1
20070244403 Natarajan et al. Oct 2007 A1
20070249946 Kumar et al. Oct 2007 A1
20070250121 Miesel et al. Oct 2007 A1
20070255120 Rosnov Nov 2007 A1
20070255153 Kumar et al. Nov 2007 A1
20070255184 Shennib Nov 2007 A1
20070255531 Drew Nov 2007 A1
20070260133 Meyer Nov 2007 A1
20070260155 Rapoport et al. Nov 2007 A1
20070260289 Giftakis et al. Nov 2007 A1
20070270678 Fadem et al. Nov 2007 A1
20070273504 Tran Nov 2007 A1
20070276273 Watson, Jr Nov 2007 A1
20070282173 Wang et al. Dec 2007 A1
20070293738 Bardy Dec 2007 A1
20070299325 Farrell et al. Dec 2007 A1
20080004499 Davis Jan 2008 A1
20080004547 Dinsmoor et al. Jan 2008 A1
20080004904 Tran Jan 2008 A1
20080021336 Dobak Jan 2008 A1
20080024293 Stylos Jan 2008 A1
20080024294 Mazar Jan 2008 A1
20080033260 Sheppard et al. Feb 2008 A1
20080039700 Drinan et al. Feb 2008 A1
20080058614 Banet et al. Mar 2008 A1
20080058656 Costello et al. Mar 2008 A1
20080059239 Gerst et al. Mar 2008 A1
20080091089 Guillory et al. Apr 2008 A1
20080103399 Patangay et al. May 2008 A1
20080114220 Banet et al. May 2008 A1
20080120784 Warner et al. May 2008 A1
20080139934 McMorrow et al. Jun 2008 A1
20080146892 LeBoeuf et al. Jun 2008 A1
20080167538 Teller et al. Jul 2008 A1
20080171918 Teller et al. Jul 2008 A1
20080171922 Teller et al. Jul 2008 A1
20080171929 Katims Jul 2008 A1
20080183052 Teller et al. Jul 2008 A1
20080200774 Luo Aug 2008 A1
20080214903 Orbach Sep 2008 A1
20080220865 Hsu Sep 2008 A1
20080221399 Zhou et al. Sep 2008 A1
20080221402 Despotis Sep 2008 A1
20080224852 Dicks et al. Sep 2008 A1
20080228084 Bedard et al. Sep 2008 A1
20080275465 Paul et al. Nov 2008 A1
20080287751 Stivoric et al. Nov 2008 A1
20080287752 Stroetz et al. Nov 2008 A1
20080293491 Wu et al. Nov 2008 A1
20080294019 Tran Nov 2008 A1
20080294020 Sapounas Nov 2008 A1
20080318681 Rofougaran et al. Dec 2008 A1
20080319279 Ramsay et al. Dec 2008 A1
20080319282 Tran Dec 2008 A1
20080319290 Mao et al. Dec 2008 A1
20090005016 Eng et al. Jan 2009 A1
20090018410 Coene et al. Jan 2009 A1
20090018456 Hung Jan 2009 A1
20090048526 Aarts Feb 2009 A1
20090054737 Magar et al. Feb 2009 A1
20090062670 Sterling et al. Mar 2009 A1
20090073991 Landrum et al. Mar 2009 A1
20090076336 Mazar et al. Mar 2009 A1
20090076340 Libbus et al. Mar 2009 A1
20090076341 James et al. Mar 2009 A1
20090076342 Amurthur et al. Mar 2009 A1
20090076343 James et al. Mar 2009 A1
20090076345 Manicka et al. Mar 2009 A1
20090076346 James et al. Mar 2009 A1
20090076348 Manicka et al. Mar 2009 A1
20090076349 Libbus et al. Mar 2009 A1
20090076350 Bly et al. Mar 2009 A1
20090076363 Bly et al. Mar 2009 A1
20090076364 Libbus et al. Mar 2009 A1
20090076397 Libbus et al. Mar 2009 A1
20090076401 Mazar et al. Mar 2009 A1
20090076405 Amurthur et al. Mar 2009 A1
20090076410 Libbus et al. Mar 2009 A1
20090076559 Libbus et al. Mar 2009 A1
20090177145 Ohlander et al. Jul 2009 A1
20090182204 Semler et al. Jul 2009 A1
20090234410 Libbus et al. Sep 2009 A1
20090264792 Mazar Oct 2009 A1
20090292194 Libbus et al. Nov 2009 A1
20100056881 Libbus et al. Mar 2010 A1
20100191310 Bly Jul 2010 A1
20110144470 Mazar et al. Jun 2011 A1
20110245711 Katra et al. Oct 2011 A1
20110270049 Katra et al. Nov 2011 A1
Foreign Referenced Citations (16)
Number Date Country
2003-220574 Oct 2003 AU
1487535 Dec 2004 EP
1579801 Sep 2005 EP
2005-521448 Jul 2005 JP
WO 0079255 Dec 2000 WO
WO 0189362 Nov 2001 WO
WO 02092101 Nov 2002 WO
WO 03082080 Oct 2003 WO
WO 2005051164 Jun 2005 WO
WO 2005104930 Nov 2005 WO
WO 2006008745 Jan 2006 WO
WO 2006102476 Sep 2006 WO
WO 2006111878 Nov 2006 WO
WO 2007041783 Apr 2007 WO
WO 2007106455 Sep 2007 WO
2009116906 Sep 2009 WO
Non-Patent Literature Citations (185)
Entry
International Search Report and Written Opinion of PCT Application No. PCT/US08/76243, dated Nov. 12, 2008, 12 pages total.
AD5934: 250 kSPS 12-Bit Impedance Converter Network Analyzer, Analog Devices, retrieved from the Internet: <<http://www.analog.com/static/imported-files/data—sheets/AD5934.pdf>>, 40 pages.
Something in the way he moves, The Economist, 2007, retrieved from the Internet: <<http://www.economist.com/science/printerFriendly.cfm?story id=9861412>>.
Abraham, “New approaches to monitoring heart failure before symptoms appear,” Rev Cardiovasc Med. 2006 ;7 Suppl 1 :33-41.
Adams, Jr. “Guiding heart failure care by invasive hemodynamic measurements: possible or useful?”, Journal of Cardiac Failure 2002; 8(2):71-73.
Adamson et al., “Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device ,” Circulation. 2004;110:2389-2394.
Adamson et al., “Ongoing right ventricular hemodynamics in heart failure,” J Am Coll Cardiol, 2003; 41:565-57.
Adamson, “Integrating device monitoring into the infrastructure and workflow of routine practice,” Rev Cardiovasc Med. 2006 ;7 Suppl 1:42-6.
Adhere [presentation], “Insights from the adhere Registry: Data from over 100,000 patient cases,” 70 pages total.
Advamed White Sheet, “Health Information Technology: Improving Patient Safety and Quality of Care,” Jun. 2005, 23 pages.
Aghababian, “Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department,” Rev Cardiovasc Med. 2002;3 Suppl 4:S3-9.
Albert, “Bioimpedance to prevent heart failure hospitalization,” Curr Heart Fail Rep. Sep. 2006;3(3):136-42.
American Heart Association, “Heart Disease and Stroke Statistics—2006 Update,” 2006, 43 pages.
American Heart Association, “Heart Disease and Stroke Statistics—2007 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation 2007; 115;e69-e171.
Belalcazar et al., “Monitoring lung edema using the pacemaker pulse and skin electrodes,” Physiol. Meas. 2005; 26:S153-S163.
Bennet, “Development of implantable devices for continuous ambulatory monitoring of central hemodynamic values in heart failure patients,” PACE Jun. 2005; 28:573-584.
Bourge, “Case studies in advanced monitoring with the chronicle device,” Rev Cardiovasc Med. 2006 ;7 Suppl 1:S56-61.
Braunschweig, “Continous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure,” European Heart Journal 2002 23(1):59-69.
Braunschweig, “Dynamic changes in right ventricular pressures during haemodialysis recorded with an implantable haemodynamic monitor ,” Nephrol Dial Transplant 2006; 21:176-183.
Brennan, “Measuring a Grounded Impedance Profile Using the AD5933,” Analog Devices, retrieved from the internet <<http://http://www.analog.com/static/imported-files/application—notes/427095282381510189AN847—0.pdf>>, 12 pages total.
Buono et al., “The effect of ambient air temperature on whole-body bioelectrical impedance,” Physiol. Meas. 2004;25:119-123.
Burkhoff et al., “Heart failure with a normal ejection fraction: Is it really a disorder of diastolic function?” Circulation 2003; 107:656-658.
Burr et al., “Heart rate variability and 24-hour minimum heart rate,” Biological Research for Nursing, 2006; 7(4):256-267.
Cardionet, “CardioNet Mobile Cardiac Outpatient Telemetry: Addendum to Patient Education Guide”, CardioNet, Inc., 2007, 2 pages.
Cardionet, “Patient Education Guide”, CardioNet, Inc., 2007, 7 pages Undated.
Charach et al., “Transthoracic monitoring of the impedance of the right lung in patients with cardiogenic pulmonary edema,” Crit Care Med Jun. 2001;29(6):1137-1144.
Charlson et al., “Can disease management target patients most likely to generate high costs? The Impact of Comorbidity,” Journal of General Internal Medicine, Apr. 2007, 22(4):464-469.
Chaudhry et al., “Telemonitoring for patients with chronic heart failure: a systematic review,” J Card Fail. Feb. 2007; 13(1): 56-62.
Chung et al., “White coat hypertension: Not so benign after all?,” Journal of Human Hypertension (2003) 17, 807-809.
Cleland et al., “The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe—Part 1: patient characteristics and diagnosis,” European Heart Journal 2003 24(5):442-463.
Cowie et al., “Hospitalization of patients with heart failure. A population-based study,” European Heart Journal 2002 23(11):877-885.
Dimri, Chapter 1: Fractals in geophysics and seimology: an introduction, Fractal Behaviour of the Earth System, Springer Berlin Heidelberg 2005, pp. 1-22. [Summary and 1st page Only].
EL-Dawlatly et al., “Impedance cardiography: noninvasive assessment of hemodynamics and thoracic fluid content during bariatric surgery,” Obesity Surgery, May 2005, 15(5):655-658.
Erdmann, “Editorials: The value of diuretics in chronic heart failure demonstrated by an implanted haemodynamic monitor,” European Heart Journal 2002 23(1):7-9.
FDA—Medtronic Inc., Chronicle 9520B Implantable Hemodynamic Monitor Reference Manual, 2007, 112 pages.
FDA Executive Summary Memorandum, prepared for Mar. 1, 2007, meeting of the Circulatory Systems Devices Advisory Panel, P050032 Medtronic, Inc. Chronicle Implantable Hemodynamic Monitor (IHM) System, 23 pages. Retrieved from the Internet: <<http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4284b1—02.pdf>>.
FDA Executive Summary, Medtronic Chronicle Implantable Hemodynamic Monitoring System P050032: Panel Package Sponsor Executive Summary; vol. 1, section 4: Executive Summary. 12 pages total. Retrieved from the Internet: <<http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4284b1—03.pdf>>.
FDA—Medtronic Chronicle Implantable Hemodynamic Monitoring System P050032: Panel Package Section 11: Chronicle IHM Summary of Safety and Effectiveness, 77 pages.
FDA, Draft questions for Chronicle Advisory Panel Meeting, 3 pages. Retrieved from the Internet: <<http://www.fda.gov/ohrms/dockets/ac/07/questions/2007-4284q1—draft.pdf>>.
FDA, References for Mar. 1 Circulatory System Devices Panel, 1 page total. 2007. Retrieved from the Internet: <<http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4284bib1—01.pdf>>.
FDA, Circulatory System Devices Advisory Panel Meeting Roster, Mar. 1, 2007. Retrieved from the Internet: <<http://www.fda.gov/ohrms/dockets/AC/07/roster/2007-4284r1—draft.pdf>>.
Fonarow et al., “Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis,” JAMA. Feb. 2, 2005;293(5):572-580.
Fonarow, “How well are chronic heart failure patients being managed?”, Rev Cardiovasc Med. 2006;7 Suppl 1:S3-11.
Fonarow, “Maximizing Heart Failure Care” [Powerpoint Presentation], downloaded from the Internet <<http://www.medreviews.com/media/MaxHFCore.ppt>>, 130 pages total.
Fonarow, “Proactive monitoring and management of the chronic heart failure patient,” Rev Cardiovasc Med. 2006; 7 Suppl 1:S1-2.
Fonarow, “The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure,” Rev Cardiovasc Med. 2003;4 Suppl 7:S21-S30.
Ganion et al., “Intrathoracic impedance to monitor heart failure status: a comparison of two methods in a chronic heart failure dog model,” Congest Heart Fail. Jul.-Aug. 2005;11(4):177-81, 211.
Gass et al., “Critical pathways in the management of acute decompensated heart failure: A CME-Accredited monograph,” Mount Sinai School of Medicine, 2004, 32 pages total.
Gheorghiade et al., “Congestion is an important diagnostic and therapeutic target in heart failure,” Rev Cardiovasc Med. 2006 ;7 Suppl 1 :12-24.
Gilliam, III et al., “Changes in heart rate variability, quality of life, and activity in cardiac resynchronization therapy patients: results of the HF-HRV registry,” Pacing and Clinical Electrophysiology, Jan. 18, 2007; 30(1): 56-64.
Gilliam, III et al., “Prognostic value of heart rate variability footprint and standard deviation of average 5-minute intrinsic R-R intervals for mortality in cardiac resynchronization therapy patients.,” J Electrocardiol. Oct. 2007;40(4):336-42.
Gniadecka, “Localization of dermal edema in lipodermatosclerosis, lymphedema, and cardiac insufficiency high-frequency ultrasound examination of intradermal echogenicity,” J Am Acad oDermatol, Jul. 1996; 35(1):37-41.
Goldberg et al., “Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: The Weight Monitoring in Heart Failure (WHARF) Trial,” American Heart Journal, Oct. 2003; 416(4):705-712.
Grap et al., “Actigraphy in the Critically III: Correlation With Activity, Agitation, and Sedation,” American Journal of Critical Care. 2005;14: 52-60.
Gudivaka et al., “Single- and multifrequency models for bioelectrical impedance analysis of body water compartments,” J Appl Physiol, 1999;87(3):1087-1096.
Guyton et al., Unit V: The Body Fluids and Kidneys, Chapter 25: The Body Fluid Compartments: Extracellular and Intracellular Fluids; Interstitial Fluid and Edema, Guyton & Hall Textbook of Medical Physiology 11th Edition, Saunders 2005; pp. 291-306.
Hadase et al., “Very low frequency power of heart rate variability is a powerful predictor of clinical prognosis in patients with congestive heart Failure,” Circ J 2004; 68(4):343-347.
Hallstrom et al., “Structural relationships between measures based on heart beat intervals: potential for improved risk assessment,” IEEE Biomedical Engineering 2004, 51(8):1414-1420.
HFSA 2006 Comprehensive Heart Failure Practice Guideline—Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline, Journal of Cardiac Failure 2006;12(1):10-e38.
HFSA 2006 Comprehensive Heart Failure Practice Guideline—Section 12: Evaluation and Management of Patients With Acute Decompensated Heart Failure, Journal of Cardiac Failure 2006;12(1):e86-e103.
HFSA 2006 Comprehensive Heart Failure Practice Guideline—Section 2: Conceptualization and Working Definition of Heart Failure, Journal of Cardiac Failure 2006;12(1):e10-e11.
HFSA 2006 Comprehensive Heart Failure Practice Guideline—Section 3: Prevention of Ventricular Remodeling Cardiac Dysfunction, and Heart Failure Overview, Journal of Cardiac Failure 2006;12(1):e12-e15.
HFSA 2006 Comprehensive Heart Failure Practice Guideline—Section 4: Evaluation of Patients for Ventricular Dysfunction and Heart Failure, Journal of Cardiac Failure 2006;12(1):e16-e25.
HFSA 2006 Comprehensive Heart Failure Practice Guideline—Section 8: Disease Management in Heart Failure Education and Counseling, Journal of Cardiac Failure 2006;12(1):e58-e68.
Hunt et al., “ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society,” Circulation. 2005;112:e154-e235.
Hunt et al., ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), Circulation. 2001;104:2996-3007.
Imhoff et al., “Noninvasive whole-body electrical bioimpedance cardiac output and invasive thermodilution cardiac output in high-risk surgical patients,” Critical Care Medicine 2000; 28(8):2812-2818.
Jaeger et al., “Evidence for Increased Intrathoracic Fluid Volume in Man at High Altitude,” J Appl Physiol 1979; 47(6): 670-676.
Jerant et al., “Reducing the cost of frequent hospital admissions for congestive heart failure: a randomized trial of a home telecare intervention,” Medical Care 2001, 39(11):1234-1245.
Jaio et al., “Variance fractal dimension analysis of seismic refraction signals,” WESCANEX 97: Communications, Power and Computing. IEEE Conference Proceedings., May 22-23, 1997, pp. 163-167 [Abstract Only].
Kasper et al., “A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission,” J Am Coll Cardiol, 2002; 39:471-480.
Kaukinen, “Cardiac output measurement after coronary artery bypass grafting using bolus thermodilution, continuous thermodilution, and whole-body impedance cardiography,” Journal of Cardiothoracic and Vascular Anesthesia 2003; 17(2):199-203.
Kawaguchi et al., “Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations,” Circulation. 2003;107:714-720.
Kawasaki et al., “Heart rate turbulence and clinical prognosis in hypertrophic cardiomyopathy and myocardial infarction,” Circ J. Jul. 2003l;67(7):601-604.
Kearney et al., “Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure,” J Am Coll Cardiol, 2002; 40(10):1801-1808.
Kitzman et al., “Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure,” JAMA Nov. 2002; 288(17):2144-2150.
Kööbi et al., “Non-invasive measurement of cardiac output : whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods,” Intensive Care Medicine 1997; 23(11):1132-1137.
Koyama et al., “Evaluation of heart-rate turbulence as a new prognostic marker in patients with chronic heart failure,” Circ J 2002; 66(10):902-907.
Krumholz et al., “Predictors of readmission among elderly survivors of admission with heart failure,” American Heart Journal 2000; 139 (1):72-77.
Kyle et al., “Bioelectrical Impedance Analysis—part I: review of principles and methods,” Clin Nutr. Oct. 2004;23(5):1226-1243.
Kyle et al., “Bioelectrical Impedance Analysis—part II: utilization in clinical practice,” Clin Nutr. Oct. 2004;23(5):1430-1453.
Lee et al., “Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model,” JAMA 2003;290(19):2581-2587.
Leier “The Physical Examination in Heart Failure—Part I,” Congest Heart Fail. Jan.-Feb. 2007;13(1):41-47.
Libbus, “BioZ Analysis,” Corventis, Inc., 7 pages (date unknown).
LifeShirt® Model 200 Directions for Use, “Introduction”, VivoMetrics, Inc. 9 page total.
Liu et al., “Fractal analysis with applications to seismological pattern recognition of underground nuclear explosions,” Singal Processing, Sep. 2000, 80(9):1849-1861. [Abstract Only].
Lozano-Nieto, “Impedance ratio in bioelectrical impedance measurements for body fluid shift determination,” Proceedings of the IEEE 24th Annual Northeast Bioengineering Conference, Apr. 9-10, 1998, pp. 24-25.
Lucreziotti et al., “Five-minute recording of heart rate variability in severe chronic heart failure : Correlates with right ventricular function and prognostic implications,” American Heart Journal 2000; 139(6):1088-1095.
Lüthje et al., “Detection of heart failure decompensation using intrathoracic impedance monitoring by a triple-chamber implantable defibrillator,” Heart Rhythm Sep. 2005;2(9):997-999.
Magalski et al., “Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-Month Follow-up Study of Patients With Chronic Heart Failure,” J Card Fail 2002, 8(2):63-70.
Mahlberg et al., “Actigraphy in agitated patients with dementia: Monitoring treatment outcomes,” Zeitschrift fur Gerontologie und Geriatrie, Jun. 2007; 40(3)178-184. [Abstract Only].
Matthie et al., “Analytic assessment of the various bioimpedance methods used to estimate body water,” Appl Physiol 1998; 84(5):1801-1816.
Matthie, “Second generation mixture theory equation for estimating intracellular water using bioimpedance spectroscopy,” J Appl Physiol 2005; 99:780-781.
McMurray et al., “Heart Failure: Epidemiology, Aetiology, and Prognosis of Heart Failure,” Heart 2000;83:596-602.
Miller, “Home monitoring for congestive heart failure patients,” Caring Magazine, Aug. 1995: 53-54.
Moser et al., “Improving outcomes in heart failure: it's not unusual beyond usual Care,” Circulation. 2002;105:2810-2812.
Nagels et al., “Actigraphic measurement of agitated behaviour in dementia,” International journal of geriatric psychiatry , 2009; 21(4):388-393. [Abstract Only].
Nakamura et al., “Universal scaling law in human behavioral organization,” Physical Review Letters, Sep. 28, 2007; 99(13):138103 (4 pages).
Nakaya, “Fractal properties of seismicity in regions affected by large, shallow earthquakes in western Japan: Implications for fault formation processes based on a binary fractal fracture network model,” Journal of geophysical research, Jan. 2005; 11(B1):B01310.1-B01310.15. [Abstract Only].
Naylor et al., “Comprehensive discharge planning for the hospitalized elderly: a randomized clinical trial ,” Amer. College Physicians 1994; 120(12):999-1006.
Nesiritide (NATRECOR) [Presentation] Acutely Decompensated Congestive Heart Failure: Burden of Disease, downloaded from the Internet: <<http://www.huntsvillehospital.org/foundation/events/cardiologyupdate/CHF.ppt.>>, 39 pages.
Nieminen et al., “EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population,” European Heart Journal 2006; 27(22):2725-2736.
Nijsen et al., “The potential value of three-dimensional accelerometry for detection of motor seizures in severe epilepsy,” Epilepsy Behav. Aug. 2005;7(1):74-84.
Noble et al., “Diuretic induced change in lung water assessed by electrical impedance tomography,” Physiol. Meas. 2000; 21(1):155-163.
Noble et al., “Monitoring patients with left ventricular failure by electrical impedance tomography,” Eur J Heart Fail. Dec. 1999;1(4):379-84.
O'Connell et al., “Economic impact of heart failure in the United States: time for a different approach,” J Heart Lung Transplant., Jul.-Aug. 1994; 13(4):5107-5112.
Ohlsson et al., “Central hemodynamic responses during serial exercise tests in heart failure patients using implantable hemodynamic monitors,” Eur J Heart Fail. Jun. 2003;5(3):253-259.
Ohlsson et al., “Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor,” European Heart Journal 2001 22(11):942-954.
Packet et al., “Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure,” J Am Coll Cardiol, 2006; 47(11):2245-2252.
Palatini et al., “Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension” Arch Intern Med. 2002;162:2313-2321.
Piiria et al., “Crackles in patients with fibrosing alveolitis bronchiectasis, COPD, and Heart Failure,” Chest May 1991; 99(5):1076-1083.
Pocock et al., “Predictors of mortality in patients with chronic heart failure,” Eur Heart J 2006; (27): 65-75.
Poole-Wilson, “Importance of control of fluidvolumes in heart failure,” European Heart Journal 2000; 22(11):893-894.
Raj et al., ‘Letter Regarding Article by Adamson et al, “Continuous Autonomic Assessment in Patients With Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device”’, Circulation 2005;112:e37-e38.
Raj, Correspondence—Letter Regarding Article by Adamson et al, “Continuous Autonomic Assessment in Patients With Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device”, Circulation 2005;112:e37-e38.
Ramirez et al., “Prognostic value of hemodynamic findings from impedance cardiography in hypertensive stroke,” AJH 2005; 18(20):65-72.
Rich et al., “A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure,” New Engl. J. Med. 1995;333:1190-1195.
Rodgers, [presentation] “Update on the Management of Heart Failure,” Southern Regional Area Health Education Centers at Sampson Regional Medical Center, Clinton, NC Apr. 2004, 76 pages total.
Roglieri et al., “Disease management interventions to improve outcomes in congestive heart failure,” Am J Manag Care. Dec. 1997;3(12):1831-1839.
Sahalos et al., “The Electrical impedance of the human thorax as a guide in evaluation of intrathoracic fluid volume,” Phys. Med. Biol. 1986; 31:425-439.
Saxon et al., “Remote active monitoring in patients with heart failure (rapid-rf): design and rationale,” Journal of Cardiac Failure 2007; 13(4):241-246.
Scharf et al., “Direct digital capture of pulse oximetry waveforms,” Proceedings of the Twelfth Southern Biomedical Engineering Conference, 1993., pp. 230-232.
Shabetai, “Monitoring heart failure hemodynamics with an implanted device: its potential to improve outcome,” J Am Coll Cardiol, 2003; 41:572-573.
Small, “Integrating monitoring into the Infrastructure and Workflow of Routine Practice: OptiVol,” Rev Cardiovasc Med. 2006 ;7 Supp 1: S47-S55.
Smith et al., “Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline ,” J Am Coll Cardiol, 2003; 41:1510-1518.
Someren, “Actigraphic monitoring of movement and rest-activity rhythms inaging, Alzheimer's disease, and Parkinson's disease,” IEEE Transactions on Rehabilitation Engineering, Dec. 1997; 5(4):394-398. [Abstract Only].
Starling, “Improving care of chronic heart failure: advances from drugs to devices,” Cleveland Clinic Journal of Medicine Feb. 2003; 70(2):141-146.
Steijaert et al., “The use of multi-frequency impedance to determine total body water and extracellular water in obese and lean female individuals,” International Journal of Obesity Oct. 1997; 21(10):930-934.
Stewart et al., “Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care,” Arch Intern Med. 1998;158:1067-1072.
Stewart et al., “Effects of a multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study,” The Lancet Sep. 1999, 354(9184):1077-1083.
Stewart et al., “Home-based intervention in congestive heart failure: long-term implications on readmission and survival,” Circulation. 2002;105:2861-2866.
Stewart et al., “Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure,” Arch Intern Med. 1999;159:257-261.
Stewart et al., “Trends in Hospitalization for Heart Failure in Scotland, 1990-1996. An Epidemic that has Reached Its Peak?,” European Heart Journal 2001 22(3):209-217.
Swedberg et al., “Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology,” Eur Heart J. Jun. 2005; 26(11):1115-1140.
Tang, “Case studies in advanced monitoring: OptiVol,” Rev Cardiovasc Med. 2006;7 Suppl 1:S62-S66.
The ESCAPE Investigators and ESCAPE Study Coordinators, “Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness,” JAMA 2005;294:1625-1633.
Tosi et al., “Seismic signal detection by fractal dimension analysis,” Bulletin of the Seismological Society of America; Aug. 1999; 89(4):970-977. [Abstract Only].
Van De Water et al., “Monitoring the chest with impedance,” Chest. 1973;64:597-603.
Vasan et al., “Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction,” J Am Coll Cardiol, 1999; 33:1948-1955.
Verdecchia et al., “Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension,” Journal of Hypertension 1998; 16(9):1335-1343.
Verdecchia et al., “Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension,” Hypertension. 1998;32:983-988.
Vollmann et al., “Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure,” Euorpean Heart Journal Advance Access published on Feb. 19, 2007, downloaded from the Internet:<<http://eurheartj.oxfordjournals.org/cgi/content/full/ehl506v1>>, 6 pages total.
Vuksanovic et al., “Effect of posture on heart rate variability spectral measures in children and young adults with heart disease,” International Journal of Cardiology 2005;101(2): 273-278.
Wang et al., “Feasibility of using an implantable system to measure thoracic congestion in an ambulatory chronic heart failure canine model,” PACE 2005;28(5):404-411.
Wickemeyer et al., #197—“Association between atrial and ventricular tachyarrhythmias, intrathoracic impedance and heart failure decompensation in CRT-D Patients,” Journal of Cardiac Failure 2007; 13 (6) Suppl.; S131-132.
Williams et al, “How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure,” American Heart Journal, 150(5):983.e1-983.e6.
Wonisch et al., “Continuous haemodynamic monitoring during exercise in patients with pulmonary hypertension,” Int J Cardiol. Jun. 8, 2005;101(3):415-420.
Wynne et al., “Impedance cardiography: a potential monitor for hemodialysis,” Journal of Surgical Research 2006, 133(1):55-60.
Yancy “Current approaches to monitoring and management of heart failure,” Rev Cardiovasc Med 2006; 7 Suppl 1:S25-32.
Ypenburg et al., “Intrathoracic Impedance Monitoring to Predict Decompensated Heart Failure,” Am J Cardiol 2007, 99(4):554-557.
Yu et al., “Intrathoracic Impedance Monitoring in Patients With Heart Failure: Correlation With Fluid Status and Feasibility of Early Warning Preceding Hospitalization,” Circulation. 2005;112:841-848.
Zannad et al., “Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL Study,” J Am Coll Cardiol, 1999; 33(3):734-742.
Zile, “Heart failure with preserved ejection fraction: is this diastolic heart failure?” J Am Coll Cardiol, 2003; 41(9):1519-1522.
U.S. Appl. No. 60/006,600, filed Nov. 13, 1995; inventor: Terry E. Flach.
U.S. Appl. No. 60/972,316, filed Sep. 12, 2008; inventor: Imad Libbus et al.
U.S. Appl. No. 60/972,329, filed Sep. 14, 2007; inventor: Yatheendhar Manicka et al.
U.S. Appl. No. 60/972,333, filed Sep. 14, 2007; inventor: Mark Bly et al.
U.S. Appl. No. 60/972,336, filed Sep. 14, 2007; inventor: James Kristofer et al.
U.S. Appl. No. 60/972,340, filed Sep. 14, 2007; inventor: James Kristofer et al.
U.S. Appl. No. 60/972,343, filed Sep. 14, 2007; inventor: James Kristofer et al.
U.S. Appl. No. 60/972,354, filed Sep. 14, 2007; inventor: Scott Thomas Mazar et al.
U.S. Appl. No. 60/972,359, filed Sep. 14, 2007; inventor: Badri Amurthur et al.
U.S. Appl. No. 60/972,363, filed Sep. 14, 2007; inventor: Badri Amurthur et al.
U.S. Appl. No. 60/972,512, filed Sep. 14, 2007; inventor: Imad Libbus et al.
U.S. Appl. No. 60/972,537, filed Sep. 14, 2007; inventor: Yatheendhar Manicka et al.
U.S. Appl. No. 60/972,581, filed Sep. 14, 2007; inventor: Imad Libbus et al.
U.S. Appl. No. 60/972,616, filed Sep. 14, 2007; inventor: Imad Libbus et al.
U.S. Appl. No. 60/972,629, filed Sep. 14, 2007; inventor: Mark Bly et al.
U.S. Appl. No. 61/035,970, filed Mar. 12, 2008; inventor: Imad Libbus et al.
U.S. Appl. No. 61/046,196, filed Apr. 18, 2008; inventor: Scott T. Mazar.
U.S. Appl. No. 61/047,875, filed Apr. 25, 2008; inventor: Imad Libbus et al.
U.S. Appl. No. 61/055,645, filed May 23, 2008; inventor: Mark Bly et al.
U.S. Appl. No. 61/055,656, filed May 23, 2008; inventor: Imad Libbus et al.
U.S. Appl. No. 61/055,662, filed May 23, 2008; inventor: Imad Libbus et al.
U.S. Appl. No. 61/055,666, filed May 23, 2008; inventor: Yatheendhar Manicka et al.
U.S. Appl. No. 61/079,746, filed Jul. 10, 2008; inventor: Brett Landrum.
U.S. Appl. No. 61/084,567, filed Jul. 29, 2008; inventor: Mark Bly.
Packer et al., “Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure,” J Am Coll Cardiol, 2006; 47(11):2245-2252.
EM Microelectronic—Marin SA, “Plastic Flexible LCD,” [product brochure]; retrieved from the Internet: <<http://www.emmicroelectronic.com/Line.asp?IdLine=48>>, copyright 2009, 2 pages total.
HRV Enterprises, LLC, “Heart Rate Variability Seminars,” downloaded from the Internet: <<http://hrventerprise.com/>> on Apr. 24, 2008, 3 pages total.
HRV Enterprises, LLC, “LoggerPro HRV Biosignal Analysis,” downloaded from the Internet: <<http://hrventerprise.com/products.html>> on Apr. 24, 2008, 3 pages total.
3M Corporation, “3M Surgical Tapes—Choose the Correct Tape” quicksheet (2004).
Cooley, “The Parameters of Transthoracic Electical Conduction,” Annals of the New York Academy of Sciences, 1970, 170(2):702-713.
The Criteria Committee of the New York Heart Association, Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th Edition, Eds. Dolgin et al., Little, Brown and Company, Boston, 1994, pp. 253-255.
Varughese, Sheeba, “Management of Acute Decompensated Heart Failure,” Crit Care Nurs Q, vol. 30, No. 2, Mar. 7, 2007, pp. 94-103.
Related Publications (1)
Number Date Country
20090076344 A1 Mar 2009 US
Provisional Applications (3)
Number Date Country
60972512 Sep 2007 US
60972537 Sep 2007 US
61055666 May 2008 US